Top

Larissa A. Meyer, MD, MPH, FACOG, FACS

Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery

About Dr. Meyer

Dr. Meyer is a Professor of Gynecologic Oncology. She cares for women with gynecologic malignancies in a compassionate and coordinated fashion by providing surgical care as well as chemotherapy. In addition to open surgery, Dr. Meyer performs specialized procedures in minimally invasive surgery, including robotic surgery and sentinel lymph node mapping, for appropriate patients with gynecologic cancers. Dr. Meyer serves as the co-lead for Enhanced Recovery After Surgery within the department.

Her research interests include health services research, patient reported outcomes, shared medical decision making, cancer prevention, and quality improvement. Dr. Meyer has authored and co-authored numerous articles in peer-reviewed journals. Dr. Meyer is a member of the American Society of Clinical Oncologists, the American College of Surgeons, the Society of Gynecologic Oncologists, the International Society for Quality of Life Research, the International Society for Pharmacoeconomics and Outcomes Research, and the International Gynecologic Cancer Society.

Stylized paper collage of female reproductive organs

What to expect from an endometrial biopsy

The cancer vaccine

View more View less

Present Title & Affiliation

Primary Appointment

Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor (Joint appointment), Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2011	The University of Texas School of Public Health, Houston, Texas, US, Master of Public Health in Epidemiology
2002	Harvard Medical School, Boston, Massachusetts, US, MD
1997	Pomona College, Claremont, California, US, BA in Anthropology

Postgraduate Training

2021-2022	Post-Graduate Training, ASCO - Leadership Development Program, Alexandria, Virginia
2014-2015	Leadership Training, Heart of Leadership, University of Texas MD Anderson Cancer Center, Houston, Tennessee
2013-2013	Executive Education, Value Measurement for Health Care, Harvard Business School Executive Education, Boston, Massachusetts
2007-2011	Clinical Fellowship, Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2002-2006	Residency, Obstetrics and Gynecology, New York Presbyterian Hospital, New York, New York

Board Certifications

2024	Alabama Board of Medical Examiners
2023	Georgia Composite Medical Board
2023	Arizona Board of Medical Examiners
2023	Louisiana State Board of Medical Examiners
2023	Tennessee Board of Medical Examiners
2023	Washington State Department of Health
2021	Florida Board of Medicine
2014	American Board of Obstetrics & Gynecology (Gynecologic Oncology Subspecialty)
2012	American Board of Obstetrics and Gynecology

Experience & Service

Academic Appointments

Associate Professor, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024

Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024

Assistant Professor, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2018

Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2018

Assistant Professor, Department of Obstetrics, Gynecology & Reproductive Sciences, The University of Texas Medical School, Houston, TX, 2011 - 2013

Administrative Appointments/Responsibilities

Inpatient Medical Director, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present

Cancer Network Clinical Consultant - West Region, Department of Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2022

Medical Director, Mid-Level Program, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024

Administrative Chief Fellow, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2011

Administrative Chief Resident, New York Presbyterian Hospital, Columbia University, New York, NY, 2005 - 2006

Other Appointments/Responsibilities

Super User, One Connect (EPIC) Electronic Health Record Transition, Houston, TX, 2015 - Present

EHR Officer, One Connect (EPIC) Electronic Health Record Transition, Houston, TX, 2014 - Present

Institutional Committee Activities

Co-Chair, Division of Surgery Diversity Equity and Inclusion Committee, 2023 - 2023

Member, Internal Advisory Board for the Shared Decision-Making Core, MDACC Cancer Center Support Grant (CCSG), 2021 - Present

Equity and Inclusion Division Council, Institutional Faculty Diversity, 2021 - 2023

Member, AMA E/M Change Sub Committee, 2020 - Present

Member, Clinical Research Informatics & Technology Committee, 2020 - Present

Member, Vice Provost- Population Sciences Advisory Council, 2019 - Present

Member, Adopt-a-Patient/Family Program in Gyn Onc, 2019 - Present

Member, Institutional Patient Survey Governance Committee, 2018 - Present

Member, Grand Rounds Committee, 2017 - Present

Co-Chair, Division of Surgery EPIC Committee, 2016 - 2020

Member, Institutional Pharmacy & Therapeutics Committee, 2014 - 2020

Co-Chair of Dept. of Gynecologic Oncology, Enhanced Recovery Team - All Teams, 2014 - Present

Member, Patient Care and Operations Team (PCOT), 2013 - Present

Chair, Prevention, HSR, QI and Survivorship Research Working Group, 2013 - 2023

Member, Innovative Surgery Working Group, 2013 - Present

Alternate, Division of Surgery Continuous Quality Improvement Committee, 2013 - 2023

Member, Developmental Therapeutics Working Group, 2013 - 2023

Member, The University of Texas MD Anderson Cancer Center Diversity Council, 2008 - 2009

Honors & Awards

2024	1st place abstract, American Society of Enhanced Recovery
2024	3rd place abstract award, American Society of Enhanced Recovery
2019	Top 1% of providers nationally ranked by patients for delivery of care, Clinical and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS)
2019	Top Editorial Board Member, International Journal Gynecological Cancer
2018	National Health Information Gold Award for Patient Education Information, Hospital/Health Care System from the Health Information Resource Center for Enhanced Recovery After Surgery Video Series
2017	Excellence in One Connect Leadership Award, MDACC President's Recognition for Faculty Excellence
2014	American Association of Medical Colleges (AAMC) Early Career Women Faculty Professional Development Seminar, AAMC
2010	Celebrating Improvement at MD Anderson, Silver Award, The University of Texas MD Anderson Cancer Center
2009	1st Place Bayer Healthcare Pharmaceuticals Inc. Award Population/Patient-Oriented Research, Trainee Research Day, The University of Texas MD Anderson Cancer Center
2009	ASCO Fellows Travel Grant
2008	ASCO/AACR Methods in Clinical Cancer Research Workshop, Vail, CO
2006	ACOG Shingo Exchange Program, 58th Annual Congress of the Japan Society of Obstetrics and Gynecology
2004	Organon Inc. Resident Research Award, Columbia University
2002	M.D., cum laude in a special field, Medical Anthropology, Harvard University
2000	Sinclair Kennedy Traveling Fellowship, Harvard University
1997	Ada May Fitts Award, awarded to the woman member of the graduating class for outstanding intellectual leadership and influence on other students at the college, Pomona College
1997	Anthropology Department Senior Prize, Pomona College for senior thesis
1997	B.A., cum laude, Pomona College
1997	Bessie Reiner Dill Award for a woman pursuing graduate studies in law, medicine or business, Pomona College
1997	Dwight L. Ryerson Memorial Pre-Medical Award for the senior premedical student who best exemplifies the humanitarian and compassionate qualities of the dedicated physician, Pomona College
1997	Mortar Board Honor Society, Pomona College
1997	Phi Beta Kappa, Pomona College
1996	Durfee Foundation Chinese Adventure Capital Program Grant, Pomona College
1996	National Science Foundation Minority Scholarship in Anthropology, Pomona College

Professional Memberships

Foundation for Women’s Cancer Education Committee

2024 - Present

American Association for Cancer Research (AACR)

2023 - Present

Academy Health

2021 - Present

Foundation for Women’s Cancer Research and Grants Committee

2021 - Present

European Society of Gynaecological Oncology

2015 - Present

International Society for Quality of Life Research

2015 - Present

International Society for Pharmacoeconomics and Outcomes Research

2014 - Present

International Gynecologic Cancer Society

2014 - Present

Harris County Members Society

2013 - Present

Society of Medical Decision Making

2013 - Present

American College of Surgeons, Council of the American College of Obstetrics and Gynecology

2009 - Present

American Society of Clinical Oncology

2007 - Present

Society of Gynecologic Oncologists

2007 - Present

American Congress of Obstetricians and Gynecologists

2006 - Present

Selected Publications

Peer-Reviewed Articles

Yeh PG, Haas A, Sun CC, Lu KH, Meyer LA, Toumazis I. Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women. Cancer Prev Res (Phila), 2025. e-Pub 2025. PMID: 39930864.
Gaillard S, Lacchetti C, Armstrong DK, Cliby WA, Edelson MI, Garcia AA, Ghebre RG, Gressel GM, Lesnock JL, Meyer LA, Moore KN, O'Cearbhaill RE, Olawaiye AB, Salani R, Sparacio D, van Driel WJ, Tew WP. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. J Clin Oncol:JCO2402589, 2025. e-Pub 2025. PMID: 39841949.
Taylor JS, Fellman B, Cain KE, Iniesta MD, Earles T, Harris M, James D, Siebel C, Lasala J, Mena G, Raty S, Popovich S, Vu K, Thosani S, Best C, Schmeler KM, Ramirez PT, Meyer LA. Glycemic control to improve post-operative outcomes in patients with type 2 diabetes mellitus: Results of the SUGAR (Surgical Universal euGlycemic Attainment during Recovery) initiative. Int J Gynecol Cancer 35(1):100003, 2025. e-Pub 2025. PMID: 39878292.
Milbury K, Ann-Yi S, Whisenant MS, Jones M, Li Y, Necroto V, Yousuf SD, Chavez-MacGregor M, Meyers L, Bruera E. Supporting patients with advanced cancer and their spouses in parenting minor children: results of a randomized controlled trial. Oncologist, 2024. e-Pub 2024. PMID: 39703166.
Saab R, Fellman BM, Legarreta AF, Meyer LA, Fleming ND, Ratan R, Nassif Haddad EF, Frumovitz M, Soliman PT. Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study. Gynecol Oncol 191:143-149, 2024. e-Pub 2024. PMID: 39396406.
Adjei NN, Haas A, Sun CC, Zhao H, Yeh PG, Giordano SH, Toumazis I, Meyer LA. Healthcare Costs in the United States by Demographic Characteristics and Comorbidity Status. Value Health 28(2):206-214, 2024. e-Pub 2024. PMID: 39532216.
Huepenbecker S, Meyer LA, Craft M, Chan JK, Craggs C, Lambert P, Lin YG. Real-world use of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. Int J Gynecol Cancer 34(11):1719-1728, 2024. e-Pub 2024. PMID: 38950920.
Ishizawa S, Niu J, Tammemagi MC, Irajizad E, Shen Y, Lu KH, Meyer LA, Toumazis I. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. J Natl Cancer Inst 116(11):1798-1806, 2024. e-Pub 2024. PMID: 39038822.
Greene KT, Pisharody N, Meyer LA, Pereira M, Dodhia R, Ferres JL, Shapiro JN. Current engagement with unreliable sites from web search driven by navigational search. Sci Adv 10(44):eadn3750, 2024. e-Pub 2024. PMID: 39475604.
Adjei NN, Haas A, Zhao H, Primm KM, Giordano SH, Sun CC, Meyer LA. Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021. Gynecol Oncol 190:255-261, 2024. e-Pub 2024. PMID: 39260122.
Huepenbecker, S, Soliman, PT, Meyer, LA, Iniesta-Donate, M, Chisholm, GB, Taylor, JS, Wilke, RN, Fleming, N. Perioperative outcomes in gynecologic pelvic exenteration before and after implementation of an enhanced recovery after surgery program. Gynecologic oncology 189:80-87, 2024. e-Pub 2024. PMID: 39042957.
Pozzar, RA, Enzinger, AC, Howard, C, Tavormina, A, Matulonis, UA, Campos, SM, Liu, J, Horowitz, NS, Konstantinopoulos, PA, Krasner, CN, Wall, JA, Sciacca, K, Meyer, LA, Lindvall, C, Wright, AA. Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers. Gynecologic oncology 188:1-7, 2024. e-Pub 2024. PMID: 38851039.
Wilke, RN, Iniesta, MD, Fellman, B, Jazaeri, AA, Meyer, LA, Fleming, N, Schmeler, KM, Taylor, JS. A colostomy for large bowel obstruction at the end of life. Gynecologic oncology 188:120-124, 2024. e-Pub 2024. PMID: 38945019.
Wall, JA, Pozzar, RA, Enzinger, AC, Tavormina, A, Howard, C, Matulonis, UA, Liu, J, Horowitz, NS, Meyer, LA, Wright, AA. Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis. Gynecologic oncology 188:125-130, 2024. e-Pub 2024. PMID: 38954989.
Andring LM, Corrigan KL, Reeve B, Meyer L, Wang XS, Smith G, Bailard N, Domingo M, Fellman B, Varkey J, Foster-Mills T, Lin L, Jhingran A, Colbert L, Eifel P, Klopp AH, Joyner M. The Value of Patient-Reported Outcomes to Predict Symptom Burden and Health-Related Quality of Life After Chemoradiation for Cervical Cancer: A Prospective Study. Pract Radiat Oncol 14(5):e353-e361, 2024. e-Pub 2024. PMID: 38825227.
Adjei NN, Haas AM, Sun CC, Zhao H, Yeh PG, Giordano SH, Toumazis I, Meyer LA. Cost of ovarian cancer by the phase of care in the United States. Am J Obstet Gynecol 232(2):204.e1-204.e13, 2024. e-Pub 2024. PMID: 39159781.
Primm, K, Zhao, H, Adjei, N, Sun, CC, Haas, A, Meyer, LA, Chang, S. Effect of Medicaid expansion on cancer treatment and survival among Medicaid beneficiaries and the uninsured. Cancer medicine 13(13), 2024. e-Pub 2024. PMID: 38970338.
Suidan, RS, Sun, CC, Schneider, A, Lu, KH, Giordano, SH, Meyer, LA. Determination of quality of life-related health utilities for surgical complications in ovarian cancer. Gynecologic oncology 185:101-107, 2024. e-Pub 2024. PMID: 38377761.
Kamboj, M, Bohlke, K, Baptiste, DM, Dunleavy, K, Fueger, A, Jones, L, Kelkar, AH, Law, LY, Lefebvre, KB, Ljungman, P, Miller, ED, Meyer, LA, Moore, H, Soares, HP, Taplitz, R, Woldetsadik, ES, Kohn, E. Vaccination of Adults With Cancer. Journal of Clinical Oncology 42(14):1699-1721, 2024. e-Pub 2024. PMID: 38498798.
Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, Kelkar AH, Law LY, LeFebvre KB, Ljungman P, Miller ED, Meyer LA, Moore HN, Soares HP, Taplitz RA, Woldetsadik ES, Kohn EC. Vaccination of Adults With Cancer: ASCO Guideline. J Clin Oncol 42(14):1699-1721, 2024. e-Pub 2024. PMID: 38498792.
Hinchcliff, EM, Knisely, A, Adjei, N, Fellman, B, Yuan, Y, Patel, A, Xu, C, Westin, SN, Sood, AK, Soliman, PT, Shafer, A, Fleming, N, Gershenson, DM, Vikram, R, Bathala, TK, Vining, D, Ganeshan, DM, Lu, KH, Sun, CC, Meyer, LA, Jazaeri, AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer 130(7):1061-1071, 2024. e-Pub 2024. PMID: 38009662.
Knisely, A, Iniesta, MD, Batman, S, Meyer, LA, Soliman, PT, Cain, K, Marten, CA, Chisholm, G, Schmeler, KM, Taylor, JS, Fleming, N. Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center. Gynecologic oncology 183:120-125, 2024. e-Pub 2024. PMID: 38368180.
Liu, W, Meyer, LA, Morse, M, Li, Y, Song, J, Engle, R, Lopez, G, Narayanan, S, Soliman, PT, Ramondetta, LM, Bruera, E, Cohen, L. Dietary Magnesium Replacement for Prevention of Hypomagnesemia in Patients with Ovarian Cancer Receiving Carboplatin-Based Chemotherapy. JCO Oncology Practice 20(4):517-524, 2024. e-Pub 2024. PMID: 38301188.
Meyer LA. Advanced Physical Assessment Competency Development: Small Clinical Group Immersion Implementation. J Nurs Educ 63(3):199, 2024. e-Pub 2024. PMID: 38442400.
Basabe MS, Suki TS, Munsell MF, Iniesta MD, Garcia Lopez JE, Hillman RT, Cain K, Huepenbecker S, Mena G, Taylor JS, Ramirez PT, Meyer LA. Evaluation of a tiered opioid prescription algorithm in an ERAS pathway: exploring opportunities for further refinement. Int J Gynecol Cancer 34(2):251-259, 2024. e-Pub 2024. PMID: 38123191.
Pozzar, RA, Wall, JA, Tavormina, A, Thompson, E, Enzinger, AC, Matulonis, UA, Campos, SM, Meyer, LA, Wright, AA. Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregivers. Gynecologic oncology 181:68-75, 2024. e-Pub 2024. PMID: 38141533.
Taylor JS, Iniesta MD, Zorrilla-Vaca A, Cain KE, Lasala JD, Mena GE, Meyer LA, Ramirez PT. Rate of venous thromboembolism on an enhanced recovery program after gynecologic surgery. Am J Obstet Gynecol 229(2):140.e1-140.e7, 2023. e-Pub 2023. PMID: 37150284.
Vranes C, Zhao H, Noer MC, Fu S, Sun CC, Harrison R, Ramirez PT, Høgdall CK, Giordano SH, Meyer LA. Secondary validation of an ovarian cancer-specific comorbidity index in a US population. Int J Gynecol Cancer 33(5):749-754, 2023. e-Pub 2023. PMID: 36863760.
Huepenbecker, S, Fu, S, Sun, CC, Zhao, H, Primm, K, Giordano, SH, Meyer, LA. ASO Visual Abstract. Annals of surgical oncology 30(3):1520-1521, 2023. e-Pub 2023. PMID: 36289120.
Huepenbecker SP, Fu S, Sun CC, Zhao H, Primm KM, Giordano SH, Meyer LA. Medicaid Expansion and Postoperative Mortality in Women with Gynecologic Cancer: A Difference-in-Difference Analysis. Ann Surg Oncol 30(3):1508-1519, 2023. e-Pub 2023. PMID: 36310311.
Pilkington M, Nelson G, Cauley C, Holder K, Ljungqvist O, Molina G, Oodit R, Brindle ME, Meyer LA, Collaborative EC. Development of an Enhanced Recovery After Surgery Surgical Safety Checklist Through a Modified Delphi Process. JAMA Netw Open 6(2):e2248460, 2023. e-Pub 2023. PMID: 36753283.
Wang XS, Ramirez PT, Shi Q, Kamal M, Garcia-Gonzalez A, Iniesta MD, Cleeland CS, Meyer LA. Patient-reported symptoms at discharge and risk of complications after gynecologic surgery. Int J Gynecol Cancer 33(2):271-277, 2023. e-Pub 2023. PMID: 36600503.
Cata JP, Hu J, Feng L, Chung C, Woodman SE, Meyer LA. Association between COVID-19 and Postoperative Neurological Complications and Antipsychotic Medication Use after Cancer Surgery: A Retrospective Study. J Pers Med 13(2), 2023. e-Pub 2023. PMID: 36836508.
Zorrilla-Vaca A, Ramirez PT, Iniesta-Donate M, Lasala JD, Wang XS, Williams LA, Meyer L, Mena GE. Opioid-sparing anesthesia and patient-reported outcomes after open gynecologic surgery: a historical cohort study. Can J Anaesth 69(12):1477-1492, 2022. e-Pub 2022. PMID: 36224506.
Primm KM, Huepenbecker SP, Zhao H, Sun CC, Hernandez DC, Meyer LA, Chang S. Impacts of Medicaid Expansion on Stage at Cancer Diagnosis by Patient Insurance Type. Am J Prev Med 63(6):915-925, 2022. e-Pub 2022. PMID: 35871117.
Hinchcliff E, Rumpf J, Ratan R, Fleming ND, Jazaeri A, Fellman B, Meyer LA, Soliman P. Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma. Gynecol Oncol 167(3):490-495, 2022. e-Pub 2022. PMID: 36270831.
Sidey-Gibbons CJ, Sun C, Schneider A, Lu SC, Lu K, Wright A, Meyer LA. Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data. Sci Rep 12(1):21269, 2022. e-Pub 2022. PMID: 36481644.
Huepenbecker SP, Wright JD, Downer MK, Incerti D, Luhn P, Dolado I, Bastiere-Truchot L, Lin YG, Chan JK, Meyer LA. Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer. Obstet Gynecol 140(5):758-767, 2022. e-Pub 2022. PMID: 36201776.
Ho, J, Mattei, J, Tetzlaff, M, Williams, MD, Davies, MA, Diab, A, Glitza, IC, McQuade, JL, Patel, SP, Tawbi, H, Wong, MK, Fisher, SB, Hanna, EY, Keung, EZ, Ross, MI, Weiser, R, Su, SY, Frumovitz, M, Meyer, LA, Jazaeri, AA, Pettaway, CA, Guadagnolo, BA, Bishop, AJ, Mitra, D, Farooqi, AS, Bassett Jr, R, Faria, SC, Nagarajan, P, Amaria, RN. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Frontiers in Oncology 12, 2022. e-Pub 2022. PMID: 36324592.
Hayek J, Zorrilla-Vaca A, Meyer LA, Mena G, Lasala J, Iniesta MD, Suki T, Huepenbecker S, Cain K, Garcia-Lopez J, Ramirez PT. Patient outcomes and adherence to an enhanced recovery pathway for open gynecologic surgery: a 6-year single-center experience. Int J Gynecol Cancer jgc(2022):003840, 2022. e-Pub 2022. PMID: 36202425.
Monuszko KA, Fish LJ, Sparacio D, Lizaso C, Burn K, Wickenheisser NE, Meyer LA, Reed SD, Davidson BA, Havrilesky LJ. Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events. Gynecol Oncol Rep 43:101050, 2022. e-Pub 2022. PMID: 35942110.
Huepenbecker SP, Fu S, Sun CC, Zhao H, Primm KM, Giordano SH, Meyer LA. Medicaid expansion and 2-year survival in women with gynecologic cancer: a difference-in-difference analysis. Am J Obstet Gynecol 227(3):482.e1-482.e15, 2022. e-Pub 2022. PMID: 35500609.
Huepenbecker SP, Sun CC, Fu S, Zhao H, Primm K, Rauh-Hain JA, Fleming ND, Giordano SH, Meyer LA. Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States. Int J Gynecol Cancer 32(9):1153-1163, 2022. e-Pub 2022. PMID: 36166208.
Huepenbecker S, Santía MC, Harrison R, Dos Reis R, Pareja R, Iniesta MD, Meyer LA, Frumovitz M, Zorrilla-Vaca A, Ramirez PT. Impact of timing of urinary catheter removal on voiding dysfunction after radical hysterectomy for early cervical cancer. Int J Gynecol Cancer ijgc(2022):003654, 2022. e-Pub 2022. PMID: 35803608.
Handley KF, Sood AK, Molin GZD, Westin SN, Meyer LA, Fellman B, Soliman PT, Coleman RL, Fleming ND. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol 166(1):50-56, 2022. e-Pub 2022. PMID: 35599168.
Fix SM, Forget MA, Sakellariou-Thompson D, Wang Y, Griffiths TM, Lee M, Haymaker CL, Dominguez AL, Basar R, Reyes C, Kumar S, Meyer LA, Hwu P, Bernatchez C, Jazaeri AA. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling. J Immunother Cancer 10(7), 2022. e-Pub 2022. PMID: 35882447.
Huepenbecker SP, Sun CC, Fu S, Zhao H, He W, Primm K, Giordano SH, Meyer LA. Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States. Int J Gynecol Cancer 32(7):899-905, 2022. e-Pub 2022. PMID: 35331992.
Huepenbecker SP, Zhao H, Sun CC, Fu S, He W, Giordano SH, Meyer LA. Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data. JCO Clin Cancer Inform 6:e2100187, 2022. e-Pub 2022. PMID: 35297648.
Nitecki R, Fu S, Jorgensen KA, Gray L, Lefkowits C, Smith BD, Meyer LA, Melamed A, Giordano SH, Ramirez PT, Rauh-Hain JA. Employment disruption among women with gynecologic cancers. Int J Gynecol Cancer 32(1):69-78, 2022. e-Pub 2022. PMID: 34785522.
Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher S, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo A, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P and Amaria RN. Neoadjuvant Checkpoint Inhibitor Immunotherapy for Resectable Mucosal Melanoma Front. Oncol. 12:1001150(doi: 10.3389/fonc.2022.1001150), 2022. e-Pub 2022.
Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res 27(23):6354-6365, 2021. e-Pub 2021. PMID: 34518313.
Nitecki R, Floyd J, Lamiman K, Clapp MA, Fu S, Jorgensen K, Melamed A, Brady PC, Kaimal A, Del Carmen MG, Woodard TL, Meyer LA, Giordano SH, Ramirez PT, Rauh-Hain JA. Outcomes of the First Pregnancy After Fertility-Sparing Surgery for Early-Stage Cervical Cancer. Obstet Gynecol 138(4):565-573, 2021. e-Pub 2021. PMID: 34623068.
Huepenbecker SP, Iniesta MD, Zorrilla-Vaca A, Ramirez PT, Cain KE, Vaughn M, Cata JP, Mena GE, Lasala J, Meyer LA. Incidence of acute kidney injury after open gynecologic surgery in an enhanced recovery after surgery pathway. Gynecol Oncol 163(1):191-198, 2021. e-Pub 2021. PMID: 34400005.
Huepenbecker SP, Sun CC, Fu S, Zhao H, Primm K, Giordano SH, Meyer LA. Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States. Cancer 127(22):4151-4160, 2021. e-Pub 2021. PMID: 34347287.
Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol 162(1):65-71, 2021. e-Pub 2021. PMID: 33838925.
Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol 225(1):9378, 2021. e-Pub 2021. PMID: 33549538.
Huepenbecker S, Hillman RT, Iniesta MD, Chen T, Cain K, Mena G, Lasala J, Wang XS, Williams L, Taylor JS, Lu KH, Ramirez PT, Meyer LA. Impact of a tiered discharge opioid algorithmon prescriptions and patient reported outcomes after open gynecologic surgery. Int J Gynecol Cancer 31(7):1052-1060, 2021. e-Pub 2021. PMID: 34135073.
Nitecki R, Clapp MA, Fu S, Lamiman K, Melamed A, Brady PC, Kaimal A, Del Carmen MG, Woodard TL, Meyer LA, Giordano SH, Ramirez PT, Rauh-Hain JA. Outcomes of the First Pregnancy After Fertility-Sparing Surgery for Early-Stage Ovarian Cancer. Obstet Gynecol 137(6):1109-1118, 2021. e-Pub 2021. PMID: 33957660.
Nitecki R, Fleming ND, Fellman BM, Meyer LA, Sood AK, Lu KH, Rauh-Hain JA. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 161(3):660-667, 2021. e-Pub 2021. PMID: 33867146.
Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecologic Oncology 161(1):56-62, 2021. e-Pub 2021. PMID: 33536126.
Lasala J, Mena GE, Iniesta MD, Cata J, Pitcher B, Wendell W, Zorrilla-Vaca A, Cain K, Basabe M, Suki T, Meyer LA, Ramirez PT. Impact of anesthesia technique on post-operative opioid use in open gynecologic surgery in an enhanced recovery after surgery pathway. Int J Gynecol Cancer 31(4):569-574, 2021. e-Pub 2021. PMID: 33483432.
Wang XS, Kamal M, Chen TH, Shi Q, Garcia-Gonzalez A, Iniesta MD, Cleeland CS, Gottumukkala V, Meyer LA. Assessment of physical function by subjective and objective methods in patients undergoing open gynecologic surgery. Gynecologic Oncology 161(1):83-88, 2021. e-Pub 2021. PMID: 33536127.
Liu W, Qdaisat A, Ferrarotto R, Fuller CD, Guo M, Meyer LA, Narayanan S, Lopez G, Cohen L, Bruera E, Hanna EY, Yeung SJ. Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation. Cancer 127(4):528-534, 2021. e-Pub 2020. PMID: 33085092.
Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic Oncology 161(1):104-112, 2021. e-Pub 2021. PMID: 33551196.
Meyer LA, Corzo C, Iniesta MD, Munsell M, Shi Q, Pitcher B, Lasala J, Cain KE, Wang XS, Mena G, Ramirez PT. A Prospective Randomized Trial Comparing Liposomal Bupivacaine vs. Standard Bupivacaine Wound Infiltration in Open Gynecologic Surgery On An Enhanced Recovery Pathway. Am J Obstet Gynecol 224(1):70.e1-70.e11, 2021. e-Pub 2020. PMID: 32682856.
Hillman RT, Iniesta MD, Shi Q, Suki T, Chen T, Cain K, Williams L, Wang XS, Taylor JS, Mena G, Lasala J, Ramirez PT, Meyer LA. Longitudinal patient-reported outcomes and restrictive opioid prescribing after minimally invasive gynecologic surgery. Int J Gynecol Cancer 31(1):114-121, 2021. e-Pub 2021. PMID: 33158876.
Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer 31(1):92-97, 2021. e-Pub 2021. PMID: 33154095.
Cain KE, Iniesta MD, Fellman BM, Suki TS, Siverand A, Corzo C, Lasala JD, Cata JP, Mena GE, Meyer LA, Ramirez PT. Effect of preoperative intravenous vs oral acetaminophen on postoperative opioid consumption in an enhanced recovery after surgery (ERAS) program in patients undergoing open gynecologic oncology surgery. GYnecologic Oncology 160(2):464-468, 2020. e-Pub 2020. PMID: 33298309.
Zhukovsky DS, Haider A, Williams JL, Naqvi S, Joshi N, Mills S, Soliman PT, Mathew B, Bodurka D, Meyer LA, Westin S, Frumovitz M, Nowitz MB, Archie L, Fenton S, Lang K, Boving V, Bruera E. An Integrated Approach to Selecting a Prepared Medical Decision Maker. J Pain Symptom Manage 61(6):1305-1310, 2020. e-Pub 2020. PMID: 33348030.
Nitecki R, Fu S, Lefkowits C, Smith BD, Meyer LA, Melamed A, Giordano SH, Rauh-Hain JA. Employment disruption following the diagnosis of endometrial cancer. Gynecologic Oncology 160(1):199-205, 2020. e-Pub 2020. PMID: 33183765.
Harrison R, Iniesta MD, Pitcher B, Ramirez PT, Cain K, Siverand AM, Mena G, Lasala J, Meyer LA. Enhanced recovery for obese patients undergoing gynecologic cancer surgery. Int J Gynecol Cancer 30(10):1595-1602, 2020. e-Pub 2020. PMID: 32848023.
Dottino JA, He W, Sun CC, Zhao H, Fu S, Rauh-Hain JA, Suidan RS, Lu KH, Giordano SH, Meyer LA. National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer 30(8):1195-1202, 2020. e-Pub 2020. PMID: 32616627.
Segarra B, Meyer LA, Malpica A, Bhosale P. Endometrial cancer recurrence at multiple port sites. Int J Gynecol Cancer 30(6):893-896, 2020. e-Pub 2020. PMID: 32371426.
Stewart KI, Eska JS, Harrison RF, Suidan R, Abraham A, Chisholm GB, Meyer LA, Westin SN, Fleming ND, Frumovitz M, Aloia TA, Soliman PT. Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges. Int J Gynecol Cancer 30(3):352-357, 2020. e-Pub 2020. PMID: 31911539.
Harrison R, Zhao H, Sun CC, Fu S, Armbruster SD, Westin SN, Rauh-Hain JA, Lu KH, Giordano SH, Meyer LA. Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer 30(2):187-192, 2020. e-Pub 2020. PMID: 31843871.
Harrison RF, Li Y, Guzman A, Pitcher B, Rodriguez-Restrepo A, Cain KE, Iniesta MD, Lasala JD, Ramirez PT, Meyer LA. Impact of implementation of an enhanced recovery program in gynecologic surgery on healthcare costs. Am J Obstet Gynecol 222(1):66.e1-66.e9, 2020. e-Pub 2020. PMID: 31376395.
Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O'Malley DM, Wright AA. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. Am J Obstet Gynecol 221(6):625.e1-625.e14, 2019. e-Pub 2019. PMID: 31207237.
Iniesta MD, Lasala J, Mena G, Rodriguez-Restrepo A, Salvo G, Pitcher B, Washington LD, Harris M, Meyer LA, Ramirez PT. Impact of compliance with an enhanced recovery after surgery pathway on patient outcomes in open gynecologic surgery. Int J Gynecol Cancer 29(9):1417-1424, 2019. e-Pub 2019. PMID: 31601647.
Harrison RF, He W, Fu S, Zhao H, Sun CC, Suidan RS, Woodard TL, Rauh-Hain JA, Westin SN, Giordano SH, Meyer LA. National Patterns of Care and Fertility Outcomes for Reproductive-aged Women with Endometrial Cancer or Atypical Hyperplasia. Am J Obstet Gynecol 221(5):474.e1-474.e11, 2019. e-Pub 2019. PMID: 31128110.
Zhukovsky DS, Soliman PT, Mathew B, Mills S, Bodurka D, Frumovitz M, Meyer LA, Westin S, Nowitz M, Archie L, Fenton S, Lang K, Williams JL, Boving V, Bruera E. Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology Center. J Oncol Pract 15(12):e1092-e1097. e-Pub 2019. PMID: 31613720.
Dottino JA, He W, Sun CC, Zhao H, Fu S, Lu KH, Meyer LA. Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes. Gynecol Oncol 154(2):405-410, 2019. e-Pub 2019. PMID: 31208738.
Suidan RS, He W, Sun CC, Zhao H, Rauh-Hain JA, Fleming ND, Lu KH, Giordano SH, Meyer LA. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol 221(2):136.e1-136.e9, 2019. e-Pub 2019. PMID: 30965052.
Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer LA, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 10(37):3533-3546, 2019. e-Pub 2019. PMID: 31191824.
Hillman RT, Sanchez-Migallon A, Meyer LA, Iniesta MD, Cain KE, Siverand AM, Veum SPL, Suki TS, Lasala JD, Ramirez PT. Patient characteristics and opioid use prior to discharge after open gynecologic surgery in an enhanced recovery after surgery (ERAS) program. Gynecol Oncol 153(3):604-609. e-Pub 2019. PMID: 30902370.
Taylor JS, Zhang N, Rajan SS, Chavez-MacGregor M, Zhao H, Niu J, Meyer LA, Ramondetta LM, Bodurka DC, Lairson DR, Giordano SH. How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients. Gynecol Oncol 152(3):452-458, 2019. e-Pub 2019. PMID: 30876488.
Meyer LA, Shi Q, Lasala J, Iniesta MD, Lin HK, Nick AM, Williams L, Sun C, Wang XS, Lu KH, Ramirez PT. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol 152(3):501-508, 2019. e-Pub 2019. PMID: 30876495.
Wang XS, Shi Q, Williams LA, Cleeland CS, Garcia-Gonzalez A, Chen TY, Shahid DR, Ramirez PT, Iniesta MD, Siverand AM, Meyer LA. Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN). Gynecol Oncol 152(3):492-500, 2019. e-Pub 2019. PMID: 30876494.
Sun CC, Meyer LA, Daniels MS, Bodurka DC, Nebgen DR, Burton-Chase AM, Lu KH, Peterson SK. Women's preferences for cancer risk management strategies in Lynch syndrome. Gynecol Oncol 152(3):514-521, 2019. e-Pub 2019. PMID: 30876497.
Suidan RS, He W, Sun CC, Zhao H, Smith GL, Klopp AH, Fleming ND, Lu KH, Giordano SH, Meyer LA. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol 152(3):439-444, 2019. e-Pub 2019. PMID: 30876486.
Nelson G, Bakkum-Gamez J, Kalogera E, Glaser G, Altman A, Meyer LA, Taylor JS, Iniesta M, Lasala J, Mena G, Scott M, Gillis C, Elias K, Wijk L, Huang J, Nygren J, Ljungqvist O, Ramirez PT, Dowdy SC. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations-2019 update. Int J Gynecol Cancer 29(4):651-668. e-Pub 2019. PMID: 30877144.
Prescott LS, Taylor JS, Enbaya A, Marten CA, Myers KN, Meyer LA, Ramirez PT, Levenback CF, Bodurka DC, Schmeler KM. Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology. Gynecol Oncol 153(3):597-603. e-Pub 2019. PMID: 30872025.
Rauh-Hain JA, Hidrue MK, Gaccione P, Melamed A, Meyer LA, Keating NL, Giordano SH, Rice LW, Birrer MJ, Del Carmen MG. Variation in resource utilization associated with the surgical management of ovarian cancer. Gynecol Oncol 152(3):587-593, 2019. e-Pub 2019. PMID: 30579568.
Taylor JS, He W, Harrison R, Zhao H, Sun CC, Lu KH, Giordano SH, Meyer LA. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol 151(2):269-274, 2018. e-Pub 2018. PMID: 30253875.
Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol 132(3):545-554, 2018. e-Pub 2018. PMID: 30095787.
Meyer LA, He W, Sun CC, Zhao H, Wright AA, Suidan RS, Dottino J, Alejandro Rauh-Hain J, Lu KH, Giordano SH. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol 150(3):451-459, 2018. e-Pub 2018. PMID: 29961559.
Meyer LA, Lasala J, Iniesta MD, Nick AM, Munsell MF, Shi Q, Wang XS, Cain KE, Lu KH, Ramirez PT. Effect of an Enhanced Recovery After Surgery Program on Opioid Use and Patient-Reported Outcomes. Obstet Gynecol 132(2):281-290, 2018. e-Pub 2018. PMID: 29995737.
Suidan RS, Sun CC, Cantor SB, Mariani A, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol 132(1):52-58, 2018. e-Pub 2018. PMID: 29889752.
Armbruster SD, Sun CC, Westin SN, Bodurka DC, Ramondetta L, Meyer LA, Soliman PT. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol 149(3):484-490. e-Pub 2018. PMID: 29622276.
Zhang Y, Coletta AM, Allen PK, Parikh AM, Cox-Mattin M, Meyer LA, Sun CC, Basen-Engquist KM, Lu KH, Klopp AH. Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer 28(2):285-292, 2018. e-Pub 2018. PMID: 29303933.
Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, Ramondetta L, Bodurka DC, Westin SN. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol 131(1):109-116, 2018. e-Pub 2018. PMID: 29215513.
Nelson G, Dowdy SC, Lasala J, Mena G, Bakkum-Gamez J, Meyer LA, Iniesta MD, Ramirez PT. Enhanced recovery after surgery (ERAS(R)) in gynecologic oncology - Practical considerations for program development. Gynecol Oncol 147(3):617-620, 2017. e-Pub 2017. PMID: 28947172.
Suidan RS, He W, Sun CC, Zhao H, Ramondetta LM, Badgwell BD, Bodurka DC, Lu KH, Giordano SH, Meyer LA. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer 27(7):1350-1359, 2017. e-Pub 2017. PMID: 28574929.
Swanick CW, Eifel PJ, Huo J, Meyer LA, Smith GL. Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer. Gynecol Oncol 146(1):87-93, 2017. e-Pub 2017. PMID: 28506563.
Osborne EM, Klopp AH, Jhingran A, Meyer LA, Eifel PJ. Impact of treatment year on survival and adverse effects in patients with cervical cancer and paraortic lymph node metastases treated with definitive extended-field radiation therapy. Pract Radiat Oncol 7(3):173, 2017. e-Pub 2017.
Taylor JS, Rajan SS, Zhang N, Meyer LA, Ramondetta LM, Bodurka DC, Lairson DR, Giordano SH. End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer. J Clin Oncol 35(16):JCO2016702894, 2017. e-Pub 2017. PMID: 28388292.
Osborne EM, Klopp AH, Jhingran A, Meyer LA, Eifel PJ. Impact of treatment year on survival and adverse effects in patients with cervical cancer and paraortic lymph node metastases treated with definitive extended-field radiation therapy. Pract Radiat Oncol 7(3):e165-e173, 2017. e-Pub 2017. PMID: 27743802.
Suidan RS, He W, Sun CC, Zhao H, Fleming ND, Ramirez PT, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol 145(1):55-60, 2017. e-Pub 2017. PMID: 28131529.
Taylor JS, Marten CA, Munsell MF, Sun CC, Potts KA, Burzawa JK, Nick AM, Meyer LA, Myers K, Bodurka DC, Aloia TA, Levenback CF, Lairson DR, Schmeler KM. The DISINFECT Initiative: Decreasing the Incidence of Surgical INFECTions in Gynecologic Oncology. Ann Surg Oncol 24(2):362-368, 2017. e-Pub 2017. PMID: 27573526.
Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun C, O'Malley DM, Wright AA. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol 2(11):1427-1433, 2016. e-Pub 2016. PMID: 27442965.
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(28):3460-73, 2016. e-Pub 2016. PMID: 27502591.
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol 143(1):3-15, 2016. e-Pub 2016. PMID: 27650684.
Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol 34(32):3854-3863. e-Pub 2016. PMID: 27601552.
Taylor JS, Marten CS, Potts KA, Cloutier LM, Cain KE, Fenton SL, Tatum TN, James DA, Myers KN, Hubbs CA, Burzawa JK, Vachhani S, Nick AM, Meyer LA, Graviss LS, Ware KM, Park AK, Aloia TA, Bodurka DC, Levenback CF, Schmeler KM. What Is the Real Rate of Surgical Site Infection?. J Oncol Pract 12(10):e878-e883. e-Pub 2016. PMID: 27460495.
Taylor JS, Zhang N, Meyer LA, Ramondetta LM, Bodurka DC, Rajan S, Giordano SH. Changing patterns of hospice and end of life care. J Clin Oncol 34, 2016. e-Pub 2016.
Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Frumovitz MM, Lu KH, Bodurka DC. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv 10(2):261-270, 2016. e-Pub 2016. PMID: 26245979.
Meyer LA, He W, Sun CC, Zhao H, Suidan RS, Lu KH, Giordano SH, Bodurka DC. Uptake and outcomes associated with neoadjuvant chemotherapy in the elderly: A population-based analysis. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer 141(1):169, 2016. e-Pub 2016.
Nelson G, Altman AD, Nick A, Meyer LA, Ramirez PT, Achtari C, Antrobus J, Huang J, Scott M, Wijk L, Acheson N, Ljungqvist O, Dowdy SC. Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations - Part II. Gynecol Oncol 140(2):323-32, 2016. e-Pub 2016. PMID: 26757238.
Nelson G, Altman AD, Nick A, Meyer LA, Ramirez PT, Achtari C, Antrobus J, Huang J, Scott M, Wijk L, Acheson N, Ljungqvist O, Dowdy SC. Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations - Part I. Gynecol Oncol 140(2):313-22, 2016. e-Pub 2016. PMID: 26603969.
Gockley AA, Rauh-Hain JA, Anders AM, Meyer LA, Clemmer J, Lu KH, Clark RM, Schorge JO, Del Carmen MG. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis. Int J Gynecol Cancer 26(4):697-704, 2016. e-Pub 2016. PMID: 26825834.
Meyer L, Suidan R, Sun C, Westin S, Coleman RL, Mills GB. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Rev Qual Life Cancer Care 1(3):231-238, 2016. e-Pub 2016. PMID: 30906877.
Rauh-Hain JA, Pepin KJ, Meyer LA, Clemmer JT, Lu KH, Rice LW, Uppal S, Schorge JO, Del Carmen MG. Management for Elderly Women With Advanced-Stage, High-Grade Endometrial Cancer. Obstet Gynecol 126(6):1198-206, 2015. e-Pub 2015. PMID: 26551187.
Rauh-Hain JA, Starbuck KD, Meyer LA, Clemmer J, Schorge JO, Lu KH, Del Carmen MG. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: A National Cancer Database analysis. Gynecol Oncol 139(1):84-89, 2015. e-Pub 2015. PMID: 26307402.
Rauh-Hain JA, Diver E, Meyer LA, Clemmer J, Lu KH, Del Carmen MG, Schorge JO. Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: Analysis of the National Cancer Database. Gynecol Oncol 139(1):77-83, 2015. e-Pub 2015. PMID: 26325526.
Ramondetta LM, Meyer LA, Schmeler K, Sun CC. Avoidable Tragedies, Disparities in Healthcare Access Among Medically Underserved Women Diagnosed with Cervical Cancer. Gynecol Oncol 139(3):500-505. e-Pub 2015. PMID: 26498912.
3rd AR, Sun CC, Burzawa JK, Fleming ND, Nick AM, Rallapalli V, Westin SN, Meyer LA, Ramirez PT, Soliman PT. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol 138(3):727-30, 2015. e-Pub 2015. PMID: 26197762.
Kim YJ, Munsell MF, Park JC, Meyer LA, Sun CC, Brown AJ, Bodurka DC, Williams JL, Bruera E, Ramondetta LM. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol 139(3):553-558, 2015. e-Pub 2015. PMID: 26432043.
Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland C, Weeks JC, O'Malley DM. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol, 2015. e-Pub 2015. PMID: 26240233.
Meyer LA, Bohlke K, Powell MA, Fader AN, Franklin GE, Lee LJ, Matei D, Coallier L, Wright AA. Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol. e-Pub 2015. PMID: 26150442.
Smith GL, Jiang J, Giordano SH, Meyer LA, Eifel PJ. Trends in the quality of treatment for patients with intact cervical cancer in the United States, 1999 through 2011. Int J Radiat Oncol Biol Phys 92(2):260-7, 2015. e-Pub 2015. PMID: 25968823.
Y Wang Y, Y Ye Y, Meyer LA, X Wu X, K Lu K, Liang AD. Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome. Mol Carcinog:430-439, 2015. e-Pub 2015. PMID: 25867973.
Meyer LA, Nick AM, Shi Q, Wang XS, Williams L, Brock T, Iniesta MD, Rangel K, Lu KH, Ramirez PT. Perioperative trajectory of patient reported symptoms: A pilot study in gynecologic oncology patients. Gynecol Oncol 136(3):440-5, 2015. e-Pub 2015. PMID: 25647455.
Hobeika M, Meyer LA. Massive lympohocele causing anorexia and deep-vein thrombosis after pelvic surgery. Surgery 157(3):601-2, 2015. e-Pub 2015. PMID: 25879113.
Bishop AJ, Allen PK, Klopp AH, Meyer LA, Eifel PJ. Relationship Between Low Hemoglobin Levels and Outcomes after Treatment with Radiation or Chemoradiation in Patients with Cervical Cancer: Has the Impact of Anemia Been Overstated?. Int J Radiat Oncol Biol Phys 91(1):196-205, 2015. e-Pub 2015. PMID: 25446609.
AI Blanco AI, Meyer L, V George V, B Teh B, A Rios A, K Ferachi K, M Rodriguez M, A Gonzalez A, Dalrymple AJ. The use of modern imaging technologies in radiation therapy of cervical cancer. Journal of Radiation Oncology, 2015. e-Pub 2015.
Jones N, Fleming N, Nick A, Munsell M, Rallapalli V, Westin S, Meyer LA, Schmeler K, Ramirez PT, Soliman P. Conversion from robotic surgery to laparotomy: A case-control study evaluating risk factors for conversion. Gynecol Oncol 134(2):238-242, 2014. e-Pub 2014. PMID: 24937481.
Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer 24(4):713-717, 2014. e-Pub 2014. PMID: 24651628.
Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS, Iglesias D, Broaddus RR, Lu KH. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol 209(1):24.e1-24.e12, 2013. e-Pub 2013. PMID: 23500454.
Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107(10):1776-1782, 2012. e-Pub 2012. PMID: 23047548.
Wang LE, Ma H, Hale KS, Yin M, Meyer LA, Liu H, Li J, Lu KH, Hennessy BT, Li X, Spitz MR, Wei Q, Mills GB. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol 138(3):377-385, 2012. e-Pub 2012. PMID: 22146979.
Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121(2):358-363, 2011. e-Pub 2011. PMID: 21276604.
Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, Anderson ML, Ramondetta LM, Tortolero-Luna G, Urbauer DL, Chang S, Gershenson DM, Brown J, Lu KH. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol 204(4):355.e1-357, 2011. e-Pub 2011. PMID: 21324431.
Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, Lu KH. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila) 4(3):463-70, 2011. e-Pub 2011. PMID: 21278312.
Yin J, Lu K, Lin J, Wu L, Hildebrandt MA, Chang DW, Meyer L, Wu X, Liang D. Genetic variants in TGF-β pathway are associated with ovarian cancer risk. PLoS One 6(9):e25559, 2011. e-Pub 2011. PMID: 21984931.
Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, Lu K. Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res 70(23):9765-9776, 2010. e-Pub 2010. PMID: 21118967.
Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28(22):3570-3576, 2010. e-Pub 2010. PMID: 20606085.
Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, Nogueras-Gonzalez GM, Schmeler KM, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol 115(5):945-952, 2010. e-Pub 2010. PMID: 20410767.
Tung CS, Sun CC, Schlumbrecht MP, Meyer LA, Bodurka DC. Survival after intestinal perforation: can it be predicted?. Gynecol Oncol 115(3):349-353, 2009. e-Pub 2009. PMID: 19765809.
Zhang Q, Shen Q, Celestino J, Milam MR, Westin SN, Lacour RA, Meyer LA, Shipley GL, Davies PJ, Deng L, McCampbell AS, Broaddus RR, Lu KH. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol 200(2):186.e1-188, 2009. e-Pub 2009. PMID: 19185100.
Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 111(1):132-136, 2008. e-Pub 2008. PMID: 18684498.
Meyer LA, Ascher-Walsh CJ, Norman R, Idrissa A, Herbert H, Kimso O, Wilkinson J. Commonalities among women who experienced vesicovaginal fistulae as a result of obstetric trauma in Niger: results from a survey given at the National Hospital Fistula Center, Niamey, Niger. Am J Obstet Gynecol 197(1):e1-4, 2007. e-Pub 2007. PMID: 17618772.
Frumovitz M, Singh DK, Meyer LA, Smith DH, Wertheim I, Resnik E, Bodurka D. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 95(3):463-468, 2004. e-Pub 2004. PMID: 15581947.
Pothuri B, Meyer L, Gerardi M, Barakat RR, Chi DS. Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. Gynecol Oncol 95(1):193-195, 2004. e-Pub 2004. PMID: 15385131.
Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, Gissmann L, Dürst M, Pothuri B, Murty VV. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 64(9):2994-2997, 2004. e-Pub 2004. PMID: 15126331.

Invited Articles

Cohn DE, Ko E, Meyer LA, Wright JD, Temkin SM, Foote J, Jones NL, Havrilesky LJ. The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations. Gynecol Oncol 145(1):185-191, 2017. e-Pub 2017. PMID: 28258763.
Suidan R, Sun C, Westin S, Coleman R, Mills G, Meyer L. The Management of Malignant Ascites and Impact on Quality of Life Outcomes in Women with Ovarian Cancer. Expert Review of Quality of Life in Cancer Care, 2016. e-Pub 2016.
Meyer LA, Westin SN, Lu KH, Milam MR. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther 8(7):1159-67, 2008. e-Pub 2008. PMID: 18588460.

Editorials

Huepenbecker SP, Meyer, LA. How Can We Pursue Equity in Cervical Cancer Prevention With Existing HPV Genotype Differences?. J Natl Cancer Inst 114(6):787-789, 2022. PMID: 35176166.
Huepenbecker SP, Meyer LA. Our dual responsibility of improving quality and questioning the metrics: Reflections on 30-day readmission rate as a quality indicator. Gynecol Oncol 165(1):1-3, 2022. PMID: 35346424.
Harrison RF, Meyer LA. Financial toxicity is common among gynecologic cancer patients. Int J Gynecol Cancer 31(6):807, 2021. PMID: 33962996.
Hinchcliff EM, Meyer LA, Westin SN. Has dose-dense chemotherapy met an ICONic end?. Lancet Oncol 21(7):869-870, 2020. PMID: 32615101.

Abstracts

Huepenbecker SP, Iniesta MD, Wang XS, Cain KE, Zorrilla-Vaca A, Shen SE, Basabe MS, Suki T, Garica Lopez JE, Mena GE, Lasala JD, Williams LA, Ramirez PT, Meyer LA. Longitudinal perioperative patient-reported outcomes in open compared with minimally invasive hysterectomy. Am J Obstet Gynecol 230(2):241.e1-241.e18, 2023. e-Pub 2023. PMID: 37827271.
Nelson G, Fotopoulou C, Taylor J, Glaser G, Bakkum-Gamez J, Meyer LA, Stone R, Mena G, Elias KM, Altman AD, Bisch SP, Ramirez PT, Dowdy SC. Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update. Gynecol Oncol 173:58-67, 2023. e-Pub 2023. PMID: 37086524.
Adjei NN, Haas A, Zhao H, Primm KM, Sun CC, Meyer LA. Trends in the use of maintenance therapy in ovarian cancer. Journal of Clinical Oncology 41, 2023. e-Pub 2023.
Meyer LA, Schneider AK, Huepenbecker SP, Adjei NN, Estrada GM, Sun CC. Making decisions about clinical trial enrollment: What’s important to the patient?. Journal of Clinical Oncology 41, 2023. e-Pub 2023.
Yeh PG, Toumazis I, Sun C, Lu K, Meyer LA. Disparities in uptake of levonorgestrel-releasing intrauterine system (LNG-IUS): implications for uterine cancer primary prevention. American Association for Cancer Research Journal, 2023. e-Pub 2023.
Meyer LA, Basabe SM, Schneider A, Westin S, Lowenstein L, Volk R, Sun C. Side effects and decision-making factors associated with maintenance therapy: patient preferences using a visual scale analog (VAS) assessment. International Journal of Gynecological Cancer, 2022. e-Pub 2022.
Sun C, Schneider A, Huepenbecher S, Westin S, Meyer LA. Hope and choices: direct patient preference elicitation for durable versus fixed survival gains in women with recurrent ovarian cancer (ROC). International Journal of Gynecological Cancer, 2022. e-Pub 2022.
Sun C, Schneider A, Basabe SM, Westin S, Lowenstein L, Volk R, Meyer LA. Do patients prefer maintenance therapy or surveillance? Weighing gain in progression-free survival and risks of adverse events via time trade-off and standard gamble assessments. International Journal of Gynecological Cancer, 2022. e-Pub 2022.
Adjei NN, Schneider AK, Westin SN, Sun CC, Meyer LA. Combating the financial burden of ovarian cancer: It takes a village, 2022. e-Pub 2022.
Heupenbecker S, Sun C, Fu S, Zhao H, Primm K, Giordano L, Meyer LA. Impact of Medicaid expansion on postoperative mortality in women with gynecologic cancer: a difference-in-difference analysis. Gynecologic Oncology 166:S16, 2022. e-Pub 2022.
Huepenbecker S, Deshmukh AA, Sun C, Rajan SS, Harrison R, Giordano S, Meyer LA. Cost-utility analysis of management strategies after frontline treatment of women with advanced epithelial ovarian cancer. Gynecologic Oncology 166:S175, 2022. e-Pub 2022.
Meyer LA, Sun CC, Lowenstein LM, Leal VB, Crocker LC, Basabe S, Schneider AK, Iniesta M, Westin SN, Volk RJ. Ovarian cancer patients’ knowledge of advanced ovarian cancer and maintenance therapy: Differences across disease and maintenance therapy status. Gynecologic Oncology 166:S234, 2022. e-Pub 2022.
Meyer LA, Lowenstein L, Sun CC, Leal V, Crocker LC, Basabe S, Alexander JD, Schneider A, Westin SN, Volk RJ. Knowledge Measure for Ovarian Cancer Research (KnoMOR): Development and psychometric testing results of a patient-centered knowledge measure. Gynecologic Oncology 166:S21, 2022. e-Pub 2022.
Basabe S, Sun CC, Volk RJ, Lowenstein L, Schneider A, Leal VB, Crocker LC, Alexander JD, Iniesta M, Meyer LA. Knowledge about advanced ovarian cancer and maintenance therapy: Does experience matter?. International Journal of Gynecologic Cancer EPV186(#240), 2021. e-Pub 2021.
Huepenbecker S, Fu S, Zhao H, Primm K, Sun C, Rauh-Hain A, Giordano S, Meyer LA. Do factors affecting time from symptom onset to diagnosis or treatment of ovarian cancer also affect survival?. Gynecologic Oncology 162 162:S1-S359, 2021. e-Pub 2021.
Huepenbecker S, Fu S, Zhao H, Primm K, Sun C, Rauh-Hain A, Giordano S, Meyer LA. Factors affecting time from symptom onset to ovarian cancer diagnosis in the United States. Gynecologic Oncology 162 162:S158-159, 2021. e-Pub 2021.
Primm K, Heupenbecker S, Zhao H, Sun C, Fu S, Meyer LA, Hernandez D, Chang S. Exploring Racial and Ethnic Differences in Time to Treatment for Breast, Colorectal, and Lung Cancer: A National Cancer Database Study. 2021 Virtual AcademyHealth Annual Research Meeting, 2021. e-Pub 2021.
SC Lu SC, C Xu C, C Nguyen C, Meyer LA, C Sidey-Gibbons C. A systematic evaluation of models predicting short-term mortality for cancer patients to highlight uncertainty about model performance and high risk of bias. Add to Collection. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
Meyer LA, Schneider AK, Molina E, Villanueva M, Lowenstein LM, Williams LA, Sun CC. A qualitative exploration of the impact of ovarian cancer on the well-being of women: evaluating the intersection and influences of social determinants of health. Gynecologic Oncology 162:S78-S79, 2021. e-Pub 2021.
Huepenbecker S, Fu S, Zhao H, Primm K, Sun C, Giordano S, Meyer LA. Temporal trends of healthcare system costs and utilization related to ovarian cancer diagnosis in the United States. International Journal of Gynecologic Cancer EPV189(#277), 2021. e-Pub 2021.
Gibbons-Sidey C, Sun CC, Cai X, Schneider A, Lu S, Subbiah IM, Wright AA, Meyer LA. Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data. Journal of Clinical Oncology 39, 2021. e-Pub 2021.
Huepenbecker S, Iniesta M, Ramirez P, Pitcher B, Vaughn M, Mena G, Lasala, J Meyer LA. Factors Associated with Acute Kidney Injury in Patients Undergoing Open Gynecologic Surgery on an Enhanced Recovery After Surgery Pathway. IGCS20 350:1374, 2020. e-Pub 2020.
Lasala J, Mena G, Pitcher B, Brown J, Meyer LA, Ramirez P. Effect of anesthesia technique by anesthesiologist on intra-operative and post-operative morphine equivalent daily dose (MEDD) and highest post-anesthesia care unit (PACU) pain score in open gynecologic surgery in an Enhanced Recovery after Surgery (ERAS) pathway. European Journal of Anesthesia 37(E-Supplement 58):351. e-Pub 2020.
Meyer LA, JD Wright JD, MK Downer MK, D Incerti D, P Luhn P, I Dolado I, L Bastiere-Truchot L, Y Lin-Liu and JK Chan Y. Patterns and adoption of BRCA testing in ovarian cancer in the real world: Observations from Flatiron Health. SGO 2020, 2020. e-Pub 2020.
Harrison RF, Noer MC, Hogdall C, Fu S, Zhao H, Sun CC, Lu KH, Giordano SH, Meyer LA. Secondary validation of an ovarian cancer-specific comorbidity index in a U.S. population. SGO 2020 207, 2020. e-Pub 2020.
Harrison RF, Zhao H, Fu S, Sun CC, Westin SN, Lu KH, Giordano SH, Meyer LA. Is an endometrial cancer diagnosis a 'teachable moment' leading to weight loss among obese women? A case-control study. SGO 2020 488, 2020. e-Pub 2020.
Sun CC, Molina E, Schneider A, Harrison RF, Westin SN, Coleman RL, Lowenstein LM, Volk RJ, Meyer LA. Patient preferences for side effects and decision-making factors associated with maintenance therapy for ovarian. SGO 2020, 2020. e-Pub 2020.
Moufarrij SM, Sood AK, Westin SN, Meyer LA, Fellman B, Soliman PT, Jazaeri AA, Coleman RL, Rauh-Hain JA, Lu KH, Fleming ND. Socioeconomic barriers to care in advanced ovarian cancer: Does a 'one size fits all' model exist when treated at a NCI-designated tertiary cancer center?. SGO 2020 533, 2020. e-Pub 2020.
Meyer LA, AK Schneider AK, E Molina E, M Villanueva M, LM Lowenstein LM, LA Williams and CC Sun LA. More toxic than treatment? The financial impact of living with ovarian cancer: A qualitative exploration of financial toxicity in women with recurrent ovarian cancer. SGO 2020 174, 2020. e-Pub 2020.
Sun CC, Molina E, Schneider A, Harrison RF, Westin SN, Coleman RL, Lowenstein LM, Volk RJ, Meyer LA. Patient preferences for maintenance therapy versus routine surveillance: Gain in progression-free survival and risks. SGO2020, 2020. e-Pub 2020.
Meyer LA, A Schneider A, TH Chen TH, X S Wang X, C Sun C. Financial toxicity and patient-reported outcomes over time: A longitudinal study of women with recurrent ovarian cancer. ASCO 38(15):6078, 2020. e-Pub 2020.
Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA. Out-of-pocket costs for PARP inhibitor treatment: Are ovarian cancer patients at risk for financial toxicity?. SGO 2020, 2020. e-Pub 2020.
Hillman RT, Iniesta MD, Suki T, Cain KE, Williams LA, Wang XS, Taylor JS, Mena GE, Lasala JD, Ramirez PT, Meyer LA. Implementation of a restrictive discharge opioid algorithm after minimally invasive gynecologic surgery: Impact on patient-reported outcomes and refill requests. SGO 2020 582, 2020. e-Pub 2020.
Villanueva M, Sun CC, Schneider A, Molina E, Wang XS, Meyer LA. Exploring the utility and burden of clinical follow up of threshold alerts generated by patient-reported outcomes in women with recurrent ovarian cancer: A longitudinal study. SGO 2020 586, 2020. e-Pub 2020.
Vaughn MM, Iniesta MD, Pitcher BN, Mena GE, Lasala JD, Ramirez PT, Meyer LA. Factors associated with acute kidney injury (AKI) in patients undergoing surgery on an enhanced recovery after. SGO 2020, 2020. e-Pub 2020.
R Nitecki R, S Fu S, BD Smith BD, LA Meyer LA, A Melamed A, JA Rauh-Hain JA. National patterns and factors predicting employment disruption in woman diagnosed with endometrial cancer. ASCO, 2020. e-Pub 2020.
JK Chan JK, LA Meyer LA, P Luhn P, C Flores C, L Bastiere-Truchot L, MK Downer MK, YG Lin YG, JD Wright JD. Uptake of targeted therapy in clinical practice among US patients with ovarian cancer. ASCO, 2020. e-Pub 2020.
A Abdelhakeem A, BD Badgwell BD, N Ikoma N, LA Meyer LA, M Zhao M, Ta A, P Das P, TL Sagebiel TL, RE Waters RE, J Estrella J, JA Ajani JA, MA Blum-Murphy MA. Survival benefit of oophorectomy in stage IV gastric cancer patients with Krukenberg tumors. ASCO, 2020. e-Pub 2020.
Harrison R, Cantor S, Sun C, Villanueva M, Stewart K, Woodard T, Shafer A, Lu K, Meyer LA. What is the fertility cost of gestational trophoblastic neoplasia surveillance for women of advanced maternal age? A decision analysis. the Society for Medical Decision Making, 2019. e-Pub 2019.
Harrison R, Iniesta MD, Cain K, Siverand A, Pitcher B, Lasala J, Ramirez PT, Meyer LA. 373 Outcomes of obese patients undergoing gynecologic surgery on an enhanced recovery after surgery (ERAS) program. IGCS, 2019. e-Pub 2019.
Fleming N, Westin S, Meyer LA, Rauh-Hain A, Shafer A, Onstad M, Cobb L, Fellman B, Bevers M, Zand B, Jazaeri A, Levenback C, Coleman R, Soliman P, Sood A. 300 Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. IGCS, 2019. e-Pub 2019.
Harrison R, LI Y, Guzman A, Pitcher B, Rodriguez-Restrepo A, Cain K, Iniesta MD, Lasala JD, Ramirez PT, Meyer LA. 52 Impact of ERAS program implementation in gynecologic surgery on healthcare costs. IGCS, 2019. e-Pub 2019.
Lowenstein LM, Sun CC, Leal VB, Crocker L, Savelieva K, Westin SN, Coleman RL, Volk RJ, Meyer LA. Decision making about maintenance therapy for ovarian cancer: qualitative exploration of factors important to patients/caregivers and clinicians. 10th International Shared Decision Making Conference, ISDM 2019, 2019. e-Pub 2019.
Lasala JD, Iniesta-Donate M, Pitcher MB, Cain KE, Mena GE, Cata JP, Siverand AM, Suki TS, Meyer LA, Ramirez PT. Effect of anesthesia technique on intra-operative and post-operative morphine equivalent daily dose (MEDD) in open gynecologic surgery in an enhanced recovery after surgery (ERAS) pathway. World Congress of Enhanced Recovery After Surgery 2019, 2019. e-Pub 2019.
Wang XS, Qiuling S, Chen, Cleeland, Garcia, Gonzalez, Ramirez P, Iniesta-Donate M, Meyer LA. Measuring functional impairment status with objective and subjective methods for perioperative care post gynecological surgery. World Congress of Enhanced Recovery After Surgery 2019, 2019. e-Pub 2019.
Taylor J, Cain, K, Ramirez PT, Earles T, Harris M, James D, Dottino J, Hubbs C, Stewart K, McGrew L, Siebel C, Enbaya A, Iniesta-Donate M, Vachhani S, Lasala J, Best C, Thosani S, Sahai S, Schmeler K, Meyer LA. Integration of a standardized diabetic management protocol into an ERAS program. World Congress of Enhanced Recovery After Surgery 2019, 2019. e-Pub 2019.
Lasala J, Qiuling S, Iniesta-Donate M, Williams LA, Wang S, Mena G, Veum S, Ramirez PT, Meyer LA. Does anesthesia technique have an effect on patient reported outcomes (PROS) in patients on an enhanced recovery after surgery (ERAS) program?. World Congress of Enhanced Recovery After Surgery 2019, 2019. e-Pub 2019.
Coleman RL, Hu W, Soliman PT, Nick AM, Ramirez PT, Westin SN, Zu Z, Schmeler KM, Bodurka DC, Meyer LA, Sood AK. Dasatinib, paclitaxel and carboplatin in women with advanced-stage and recurrent endometrial cancer: A pilot clinical and translational study. SGO 2019 Annual Meeting(51), 2019. e-Pub 2019.
Dal Molin GZ, Sood AK, Fellman B, Coleman RL, Westin SN, Meyer LA, Fleming ND. Assessment of survival after primary treatment in ovarian cancer patients using a modified frailty index. SGO 2019 Annual Meeting(344), 2019. e-Pub 2019.
Suidan RS, Sun CCL, Cantor SB, Frumovitz M, Giordano SH, Meyer LA. A cost-utility analysis of sentinel lymph node mapping versus complete lymphadenectomy in the management of early-stage cervical carcinoma. SGO 2019 Annual Meeting(313), 2019. e-Pub 2019.
Meyer LA, Q Shi Q, AK Schneider AK, HK Lin HK, E Molina E, L Williams L, K Savelieva K, PT Soliman PT, SN Westin SN, XS Wang and CCL Sun XS. Symptom trajectory in women with recurrent ovarian cancer: How does symptom burden change near the end of life?. SGO Annual Meeting 2019(258), 2019. e-Pub 2019.
Harrison R, Cantor SB, Sun CCL, Villanueva M, Stewart KI, Woodard TL, Shafer A, Lu KH, Meyer LA. What is the opportunity cost of postmolar surveillance for women of advanced maternal age seeking pregnancy? A Monte Carlo microsimulation model. SGO 2019 Annual Meeting(165), 2019. e-Pub 2019.
Harrison R, Zhao H, He W, Sun CCL, Suidan RS, Armbruster S, Rauh-Hain JA, Lu KH, Giordano SH, Meyer LA. Body mass index and intention for health behavior change before and after treatment of endometrial cancer. SGO 2019 Annual Meeting(322), 2019. e-Pub 2019.
Stewart KI, Eska J, Chisholm G, Abraham A, Fleming ND, Frumovitz M, Meyer LA, Westin SN, Aloia TA, Soliman PT. Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: Surgical outcomes and hospital charges. SGO 2019 Annual Meeting(328), 2019. e-Pub 2019.
Labrie M, Ju Z, Litton JK, Kim TB, Lee S, Chen K, Soliman PT, Frumovitz M, Meyer LA, Moulder S, Jazaeri A, KLu KH, Sood AK, Coleman RL, Mills GB, Westin SN. Exploration of markers of synergistic lethality of PARP and PI3K-akt-mTOR inhibitors in women’s cancers. SGO 2019 Annual Meeting(91), 2019. e-Pub 2019.
Harrison R, He W, Zhao H, Sun CCL, Suidan RS, Woodard TL, Rauh-Hain JA, Westin SN, Giordano SH, Meyer LA. 36 - Scientific Plenary National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or hyperplasia with atypia, 1999-2014. SGO-2019 Annual Meeeting(28), 2019. e-Pub 2019.
Meyer LA, CCL Sun CCL, K Savelieva K, V Leal V, L Crocker L, E Molina E, SN Westin SN, RL Coleman RL, RJ Volk and LM Lowenstein RJ. Patient decision making regarding maintenance therapy for ovarian cancer: A qualitative exploration. SGO 2019 Annual Meeting(34), 2019. e-Pub 2019.
Suidan RS, Sun CCL, Lu KH, Giordano SH, Meyer LA. A prospective assessment of patient preferences in ovarian cancer: What do patients value the most?. SGO 2019 Annual Meeting(260), 2019. e-Pub 2019.
Sanchez Migallon Perez A, Iniesta MD, Meyer LA, Siverand A, Suki TS, Cain KC, Lasala J, Corzo C, Ramirez PT. Opioid consumption day prior to discharge in patients undergoing open gynecologic surgery in an ERAS program: Developing a model for reduction in narcotic discharge prescriptions. ERAS - IGCS:13, 2018. e-Pub 2018.
Fleming N, Westin S, Coleman R, Soliman P, Fellman B, Meyer LA, Shafer A, Rauh-Hain A, Onstad M, Jazaeri A, Sood A. Predictors of response to neoadjuvant chemotherapy in advance stage ovarian cancer. Poster Presentations(676), 2018. e-Pub 2018.
Meyer LA, He W, Sun CC, Zhao H, Wright AA, Suidan RS, Dottino J, Alejandro Rauh-Hain J, Lu KH, Giordano SH. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol 150(3):451-459, 2018. e-Pub 2018. PMID: 29961559.
Iniesta M, Lasala J, Rodriguez-Restrepo A, Corzo C, Siverand A, Ti S, Salvo G, Munsell M, Meyer LA, Ramirez P. Correlation of compliance with enhanced recovery after surgery (ERAS) Guidelines and patient outomces in gynecologic surgery. Poster walk with Professor:62, 2018. e-Pub 2018.
Meyer LA, Lasala J, Corzo C, Munsell M, Shi Q, Iniesta MD, Cain KE, Mena G, Ramirez P. A Phase III Prospective Randomized Trial Comparing Liposomal Bupivacaine vs. Standard Bupivacaine Wound infiltration in patients undergoing open Gynecologic Surgery on an enhanced recovery pathway. IGCS - Oral Communication:11, 2018. e-Pub 2018.
SN Westin SN, JK Litton JK, RA Williams RA, CJ Shepherd CJ, W Brugger W, EJ Pease EJ, P Soliman P, M Frumovitz M, CF Levenback CF, AK Sood AK, Meyer L, S Moulder S, V Valero V, S Saleem S, AM Rodriguez AM, A Cyriac A, L Engerman L, C Samuel C, GB Mills GB, Coleman AR. Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. Journal of Clinical Oncology 15:5504-5504, 2018. e-Pub 2018.
Taylor JS, Zhang N, Rajan SS, Meyer LA, Ramondetta LM, Bodurka DC, Lairson DR, Giordano SH. How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients. 49th Annual Meeting of the Society of Gynecologic Oncology(201), 2018. e-Pub 2018.
Rauh-Hain JA, Worle Jr MJ, Melamed A, Meyer LA, del Carmen MG. Variation in unplanned readmission associated with the surgical management of women with ovarian cancer. 49th Annual Meeting of the Society of Gynecologic Oncology(362), 2018. e-Pub 2018.
Durdena E, Lenharta G, Meyer LA, Shenolikar R, Moore KN. Duration of exposure to select DNA-damaging therapy and the risk of secondary myelodysplastic syndrome and acute. 49th Annual Meeting of the Society of Gynecologic Oncology, 2018. e-Pub 2018.
Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Personalized surgical algorithm for advanced ovarian cancer: Results from a prospective quality improvement project. 49th Annual Meeting of the Society of Gynecologic Oncology(158), 2018. e-Pub 2018.
Rauh-Hain JA, Melamed A, Meyer LA, del Carmen MG. Variation of cost and resource utilization associated with the surgical management of women with ovarian cancer. Proceedings of the 2018 Society of Gynecologic Oncologists 49th Annual Meeting(#9723), 2018. e-Pub 2018.
Meyer LA, Shi Q, Lasala JD, Nick AM, Iniesta MD, Siverand AM, Corzo C, Wang XS, Lu KH, Ramirez PR. Patient-reported symptom burden and functional recovery before and after enhanced recovery after surgery (ERAS) implementation: A comparison between open and minimally invasive surgery. Proceedings of the 2018 Society of Gynecologic Oncologists 49th Annual Meeting(#10016), 2018. e-Pub 2018.
Gockley AA, Cronin A, Bookman MA, Burger RA, Cristea M, Griggs JJ, Mantia-Smaldone GM, Meyer LA, O'Malley DM, Wright AA. Outcomes of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. 49th Annual Meeting of the Society of Gynecologic Oncology(133), 2018. e-Pub 2018.
Dottino JA, He W, Sun CCL, Zhao HH, Rauh-Hain JA, Suidan RS, Lu KH, Giordano SH, Meyer LA. Aggressive surgery in the elderly: National trends and outcomes associated with bowel and upper abdominal procedures in ovarian cancer surgery. 49th Annual Meeting of the Society of Gynecologic Oncology(343), 2018. e-Pub 2018.
LA M, Shi Q, Iniesta M, Harris M, Sun C, Lasala J, Wang Q, Nick A, Lu K, Ramirez P. Comparison of patient reported symptom burden in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Proceedings of the 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
Suidan R, He W, Sun C, Zhao H, Lu K, Giordano S, Meyer LA. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Proceedings of the 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
Rodriguez-Restrepo A, Iniesta M, Salvo G, Sheth N, Corzo C, Lasala J, Meyer LA, Munsell M, Lu K, Ramirez P. Compliance with an enhanced recovery after surgery (ERAS) program in gynecologic surgery: impact on length of stay and complications. World Congress of Enhanced Recovery After Surgery 2017, 2017. e-Pub 2017.
Lasala J, Mena G, Iniesta M, Rodriguez-Restrepo A, Meyer LA, Salvo G, Corzo X, Munsell M, Heir J, Ifeanyi I, Cata J, Lu K, Ramirez P. Impact of an enhanced recovery after surgery (ERAS) program on postoperative renal function. World Congress of Enhanced Recovery After Surgery 2017, 2017. e-Pub 2017.
Salvo G, Meyer LA, Lasala J, Iniesta M, Sheth N, Munsell M, Rodriguez-Restrepo A, Corzo C, Lu K, Ramirez P. Implementation of an Enhanced Recovery After Surgery (ERAS) Program: The MD Anderson Cancer Center Experience. World Congress of Enhanced Receovery After Surgery 2017, 2017. e-Pub 2017.
Dood R, Meyer LA, Lasala J, Cata J, Mena G, Rodriguez A, Iniesta M, Sheth N, Salvo G, Lu K, Ramirez P. Return to intended oncologic therapy (RIOT) after surgery for gynecologic cancer in an enhanced recovery after surgery (ERAS) program. World Congress of Enhanced Recovery After Surgery 2017, 2017. e-Pub 2017.
Meyer LA, Yao L, Rodriguez A, Nick A, Lasala J, Guzman A, Calhoun J, Iniesta M, Harris M, Earles T, Lu K, Ramirez P. A cost comparison of resource utilization before and after implementing an enhanced recover after surgery (ERAS) program-A significant impact on the ‘bottom line’. World Congress of Enhanced Recovery After Surgery 2017, 2017. e-Pub 2017.
Suidan RS, Sun C, Cantor S, Mariani A, Soliman P, Westin S, Lu K, Giordano S, Meyer LA. A cost-utility analysis of sentinel lymph node mapping, selective lymphadenectomy, and routing lymphadenectomy in the management of low-risk endometrial carcinoma. Proceedings of the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, 2017. e-Pub 2017.
Prescott LS, Taylor JS, Marten CA, Munsell MF, Myers K, Meyer LA, Ramirez PT, Levenback CF, Bodurka DC, Schmeler KM. Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology. Proceedings of the Society of Gynecologic Oncologists 48th Annual Meeting, 2017. e-Pub 2017.
Suidan RS, He W, Sun C, Zhao H, Smith G, Klopp A, Fleming N, Lu K, Giordano S, Meyer LA. National Trends, Outcomes, and Costs of Radiation Therapy in the Management of Low- and High- Intermediate Risk Endometrial Carcinoma. Proceedings of the 2017 ASCO Quality Care Symposium, 2017. e-Pub 2017.
Meyer LA, Suidan RS, He W, Sun CC, Zhao H, Westin SN, Fleming ND, Soliman PT, Lu KH, Giordano SH. National patterns of care for women of child-bearing age with endometrial hyperplasia and cancer. 16th Biennial Meeting of the International Gynecologic Cancer Society, 2016. e-Pub 2016.
Meyer LA, Suidan R, He W, Sun CC, Zhao H, Westin S, Soliman P, Woodard T, Lu K, Giordano S. Endometrial hyperplasia and cancer in young women: A study of national patterns of care over time and pregnancy outcomes. 16th Biennial Meeting of the International Gynecologic Cancer Society, 2016. e-Pub 2016.
Taylor JS, Zhang N, Meyer LA, Ramondetta LM, Bodurka DC, Rajan S, Giordano SH. When more is less: End-of-life disparities among ovarian cancer patients. J Clin Oncol 34, 2016. e-Pub 2016.
Suidan RS, He W, Sun CC, Soliman PT, Ramirez PT, Zhao H, Fleming ND, Westin SN, Lu KH, Giordano SH, Meyer LA. Impact of body mass index on surgical costs and morbidity for women with endometrial carcinoma/hyperplasia. J Clin Oncol 34, 2016. e-Pub 2016.
Suidan RS, He W, Sun CCL, Zhao H, Ramondetta LM, Badgwell BD, Bodurka DC, Lu KH, Giordano SH, Meyer, LA. Treatment patterns and outcomes for bowel obstruction in elderly ovarian cancer patients: A population-based analysis. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016. e-Pub 2016.
Meyer LA, Nick AM, Iniesta MD, Cain KE, Earler TW, Lasala JD, Shi Q, Wang XS, Lu KH, Ramirez PT. Is recovery really "enhanced" through enhanced recovery programs? An analysis of patient-reported perioperative symptom burden before and after implementation of an enhanced recovery pathway for gynecologic surgery. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016. e-Pub 2016.
Soliman PT, Garcia E, Lang K, Villanueva V, Westin SN, Fleming ND, Feeley T, Lu KH, Meyer, LA. Evaluation of resource utilization using time-derived activity-based costing results in more effective processes and cost reduction. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016. e-Pub 2016.
Cain KE, Lasala JD, Nick AM, Meyer, LA, Iniesta MD, Earles TW, Munsell MF, Ramirez PT. Decreased postoperative opioid consumption following implementation of enhanced recovery pathway after gynecologic surgery. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016. e-Pub 2016.
Taylor JS, Marten CA, Sun CCL, Bodurka DC, Potts K, Nick AM, Meyer, LA, Levenback CF, Lairson DR, Schmeler KM. The cost-effectiveness of the DISINFECT Initiative (Decreasing the Incidence of Surgical INFECTions) in gynecologic oncology. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016. e-Pub 2016.
Lasala JD, Ifeanyi IC, Singh J, Earles JW, Palmer LD, Harris M, Ramirez PT, Calderon TM, Nick AM, Meyer, LA, Jackson TA. Implementation of an enhanced recovery after gynecologic oncology surgery pathway: Improving compliance with key elements of preoperative care. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016. e-Pub 2016.
Lasala JD, Nick AM, Ramirez PT, Meyer LA, Cain KE, Munsell MF, Iniesta MD, Ifeanyi IC, Singh J, Calderon TM, Kwater P, Tsai J, Vachhani S, Cata JP, Mena G. Decreased intraoperative opioid consumption following institution of enhanced recovery program in open gynecologic surgery. Proceedings of the 2016 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, 2016. e-Pub 2016.
Lasala JD, Meyer LA, Nick AM, Ramirez P, Mena GE, Cata LP, Gottumukkala V, Kwater P, Hancher-Hodges S, Cain K, Harris M, Palmer L. Implementation of an Enhanced Recovery after Gynecologic Oncology Surgery Pathway: Improving Compliance with Key Elements of Preoperative Care. Proceedings of the 2015 World Congress of Enhanced Recovery after Surgery and Perioperative Medicine Annual Meeting, 2015. e-Pub 2015.
Iniesta MD, Patrono MG, Nick AM, Washington LD, Ramos KE, Earles TW, Lasala JD, Ramirez PT, Meyer LA. Utility of Activity Logs in an Enhanced Recovery Pathway in Gynecologic Surgery. Proceedings of the 2015 World Congress of Enhanced Recovery after Surgery and Perioperative Medicine Annual Meeting, 2015. e-Pub 2015.
Meyer LA, Cronin AM, Sun CC, Bookman MA, Burger RA, Cristea M, Griggs JJ, Levenback C, Mantia-Smaldone G, Matulonis UA, Niland J, O'Malley DM, Wright AA. Use of neoadjuvant chemotherapy in advanced ovarian cancer. J Clin Oncol 33(15), 2015. e-Pub 2015.
Lasala JD, Cain KE, Meyer LA, Ramirez P, Iniesta-Donate M, Mena GE, Cata JP, Earles T, Gottumukkala V, Kwater P, Hancher-Hodges S, Speer B, Munsell M, Singh J, Nick AM. Decreased Intra-Operative Opioid Consumption Following Enhanced Surgery Within Enhanced Recovery after Gynecologic Surgery. Proceedings of the 2015 World Congress of Enhanced Recovery after Surgery and Perioperative Medicine Annual Meeting, 2015. e-Pub 2015.
Earles TW, Harris MG, Palmer LD, Meyer LA, Iniesta MD, Lasala JD, Cain KE, Washington LD, Ramirez PT, Nick AM. An Evaluation of an Enhanced Recovery Program Established for Patients Undergoing Open Gynecologic Surgery. Proceedings of the 2015 World Congress of Enhanced Recovery after Surgery and Perioperative Medicine Annual Meeting, 2015. e-Pub 2015.
Zhang Y, Allen P, Meyer LA, Sun CC, Basen-Engquist KM, Lu KH, Klopp AH. Visceral adiposity associated with increased risk of death from ovarian cancer. Gynecol Oncol 137:118, 2015. e-Pub 2015.
Wainwright A, Brimmage B, Barratt MS, Robazetti S, Gomez MP, Ramondetta LM, Schmeler KM, Meyer LA. Structured patient reminder systems and HPV vaccine completion rates: A quality improvement initiative. Gynecol Oncol 137:150, 2015. e-Pub 2015.
Ramondetta LM, Kim YJ, Munsell MF, Park J, Meyer LA, Sun CC, Brown AJ, Bodurka DC, Bruera E. Symptom burden in women with advanced or recurrent cervical cancer referred to a supportive care center. Gynecol Oncol 137:197, 2015. e-Pub 2015.
O'Malley DM, Niland J, Bookman MA, Burger RA, Cristea M, Griggs J, Mantia-Smaldone GM, Meyer LA, Sun CC, Wright A, Cohn DE. The use of NCCN guideline therapy in the first line/adjuvant setting in patients with ovarian cancer from 6 NCCN institutions. Gynecol Oncol 137:42, 2015. e-Pub 2015.
Meyer LA, He W, Zhao H, Sun CC, Wright A, Bodurka DC, Lu KH, Giordano SH. Patterns of care and survival in a matched case–control study of intraperitoneal chemotherapy in a national population-based cohort of elderly ovarian cancer patients. Gynecol Oncol 137:175-176, 2015. e-Pub 2015.
Zhang H, Gounder M, Murthy R, Helgason T, Hong D, Benjamin R, Meyer LA, Zinner R, Meric-Bernstam F. Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer. Proceedings of the 13th International Congress on Targeted Anticancer Therapies (TAT 2015), 2015. e-Pub 2015.
Meyer LA, Brimmage B, Gomez M, Hodgson S, Barratt M, Schmeler K, Ramondetta L, Sun CC. Parental Risk Perception and Decision Making Regarding Vaccination of their Eligible Children with the Human Papillomavirus Vaccine. Proceedings of the 36th Annual Meeting of the Society for Medical Decision Making, 2014. e-Pub 2014.
Brimmage B, Gomez MP, Hodgson S, Barratt MS, Dalrymple JL, Gregg A, Meyer, LA. Forgotten appointments equals missed opportunities: Exploring the reasons for low HPV vaccine series completion rates. Gynecol Oncol 133(Suppl 1):188, 2014. e-Pub 2014.
Meyer LA, Brimmage B, Gomez MP, Hodgson S, Dalrymple JL, Gregg A, Barratt MS. Barriers to human papillomavirus (HPV) vaccination: perspectives of parents of vaccine-eligible children. Gynecol Oncol 133(Suppl 1):37, 2014. e-Pub 2014.
Smith JA, Mathew LM, Gaikwad AG, Faro JP, Meyer, LA, Dalrymple JL. In vitro and in vitro evaluation of active hexose correlated compound (AHCC) for the erradication of HPV. Gynecol Oncol 133(Suppl 1):189, 2014. e-Pub 2014.
Meyer LA, He W, Zhao H, Sun CC, Buchholz T, Lu K, Giordano S. Patterns of care and overall survival in the Medicare ovarian cancer population. J Clin Oncol 32(5s), 2014. e-Pub 2014.
Meyer LA, Slomovitz B, Djordjevic B, Iglesias D, Westin S, Broaddus R, Munsell M, Wolf J, Gershenson D, Lu K. Can negative biomarkers be helpful? A novel combination test to predict non-response to inhibition of the mammalian target of rapamycin (mTOR) pathway in endometrial cancer. Gynecol Oncol 125(Suppl. 1):S163, 2012. e-Pub 2012.
Meyer LA, Schmeler K, Wallbillich J, Soliman P, Frumovitz M, Burke C, Bodurka D, Levenback C. Clinical practice guidelines decrease unnecessary Pap tests in survivors of gynecologic malignancies. Gynecol Oncol 120(Suppl 1):S30, 2011. e-Pub 2011.
Huang M, Westin S, Sun C, Meyer LA, Tung C, Urbauer D, Bodurka D. Menopausal symptoms and the use of hormone replacement therapy: The gynecologic cancer survivors’ perspective. Gynecol Oncol 120(Suppl 1):S82, 2011. e-Pub 2011.
Huang M, Djordjevic B, Urbauer D, Westin SN, Sun CC, Burzawa JK, Meyer LA, Bodurka DC, Broaddus R, Lu KH. Molecular analysis of endometrial pathogenesis in Lynch Syndrome. J Clin Oncol 29, 2011. e-Pub 2011.
Meyer LA, Slomovitz BM, Djordjevic B, Galbincea JM, Johnston TA, Munsell M, Burzawa JK, Huang M, Broaddus R, Iglesias DA, Coleman RL, Gershenson DM, Burke TW, Wolf J, Lu KH. The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer. J Clin Oncol 29, 2011. e-Pub 2011.
Meyer LA, Liang D, Lin J, Ye Y, Huang M, Pu X, Lu K, Wu X. Genetic Variants in the mammalian target of rapamycin (mTOR) pathway as predictors of clinical response and survival in women with ovarian cancer. Gynecol Oncol 120(Suppl 1):S23, 2010. e-Pub 2010.
Huang M, Burzawa J, Djordjevic B, McCampbell A, Boyd-Togers S, Meyer L, Westin S, Broaddus R, Lu K. Preinvasive disease in patients with Lynch syndrome-associated endometrial cancer. Gynecol Oncol 116(3 Supp 1):S97, 2010. e-Pub 2010.
Westin SN, Sun CC, Schlumbrecht MP, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Soliman PT, Lu KH, Bodurka DC. Persistent obesity among endometrial cancer survivors: A teachable moment?. Gynecol Oncol 116:S81, 2010. e-Pub 2010.
Burzawa J, Schmandt R, Bowser J, Zhang Q, Huang M, Meyer LA, Westin S, Gershenson D, Lu K. Preclinical evidence for exercise and pharmacologic exercise mimetics in the treatment of endometrial cancer. Gynecol Oncol 116(3 Supp 1):S80, 2010. e-Pub 2010.
Burzawa JK, Schmeler KM, Soliman PT, Lacour RA, Meyer LA, Bevers MW, Frumovitz MM, Pustilnik T, Brown J, Anderson ML, Ramondetta LM, Tortolero-Luna G, Gershenson DM, Lu KH. Prospective, population-based evaluation of insulin resistance, polycystic ovary syndrome and metabolic syndrome in a cohort of patients with endometrial cancer. Gynecol Oncol 112(2, Suppl. 1):S85, 2009. e-Pub 2009.
Burke CC, Meyer LA, Daniels MS, Schmeler KM, Garcia EA, Zook SU, Zalun G, Sam AV, Rothe ER, Anderson ME, Gershenson DM, Lu KH. Identification of women with ovarian cancer at risk for BRCA 1/2 mutations: Initial Results from a quality improvement initiative. Gynecol Oncol 112(2, Suppl. 1):S20, 2009. e-Pub 2009.
Meyer LA, Anderson ME, Lacour RA, Westin SN, Burzawa JK, Urbauer DL, Daniels MS, Burke CC, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA 1 and BRCA 2 mutations: A trend over time. Gynecol Oncol 112(2, Suppl. 1):S96, 2009. e-Pub 2009.
Liang D, Meyer LA, Lin J, Xia P, Ye Y, Wu L, Lu K, Wu X. Genetic Variants in microRNA processing pathway genes and ovarian cancer risk [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver CO Philadelphia (PA): AACR, 2009. e-Pub 2009.
Westin SN, Sun CC, Lacour RA, Meyer, LA, Tung CS, Urbauer DL, Frumovitz MM, Lu KH, Gershenson DM, Bodurka DC. Survivors of Gynecologic Malignancies: Impact of treatment on health and well- being. J Clin Oncol 26(7s, Suppl), 2008. e-Pub 2008.
Zhang Q, Celestino J, Shen Q, Milam M, Westin S, Lacour R, Meyer LA, Shipley G, Davies P, Lu K. Estrogen- induced cell proliferation and cell- cycle signaling in obese rat endometrium, 2008. e-Pub 2008.
Westin SN, Lu KH, Milam MR, Lacour, RA, Meyer, LA, Urbauer, DL, Bodurka DC, Broaddus, RR. Adenocarcinoma of the lower uterine segment: A distinct clinical entity associated with Lynch Syndrome. Gynecol Oncol 108(Suppl. 1):S64-65, 2008. e-Pub 2008.
Lacour RA, White KG, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik T, Urbauer DL, Sun CC, Bodurka DC, Gershenson DM, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 108(Suppl.1):S59, 2008. e-Pub 2008.
Meyer LA, Westin SN, Lacour RA, Urbauer DL, Schmeler KM, Daniels MS, Sun CC, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA1/2: Missed opportunities. J Clin Oncol 26(7s, Suppl), 2008. e-Pub 2008.
Lacour, RA, Westin, SN, Meyer, LA, Soliman, PT, Keeler, ER, Boyd-Rogers, SG, Urbauer, DL, Broaddus, RR, Loose, DS, Lu, KH. Alterations in estrogen-associated proliferation markers in histologically-normal endometrium of obese women. J Clin Oncol 26(May 20- suppl), 2008. e-Pub 2008.
Westin SN, Lu KH, Lacour RA, Meyer LA, Xie S, Urbauer DL, Broaddus RR. GRP78 has unique expression in normal endometrium and endometrial carcinoma. Gynecol Oncol 108(Suppl. 1):S74, 2008. e-Pub 2008.
Lacour RA, Daniels MS, Westin SN, Meyer LA, LA Choubey V, Blank SV, MacDonald HR, Roman L, Estes JM, Barnes M, Teoh D, Powell B, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Do BRCA mutations confer a survival advantage in all cases of advanced-ovarian cancer?. Gynecol Oncol 108(Suppl. 1):S108-109, 2008. e-Pub 2008.
Meyer LA, Ascher-Walsh CJ, Norman R, Idrissa A, Herbert H, Kimso O, Wilkinson J. Commonalities among women who experienced vesicovaginal fistulae as a result of obstetric trauma in Niger: results from a survey given at the National Hospital Fistula Center, Niamey, Niger. Am J Obstet Gynecol 197(1):90.e1-4, 2007. e-Pub 2007. PMID: 17618772.
Meyer LA, Pothuri B. Decompressive percutaneous gastrostomy tube use in gynecologic malignancies. Curr Treat Options Oncol 7(2):111-20, 2006. e-Pub 2006. PMID: 16455022.
Pothuri B, Meyer LA, Herzog T, Cohen C, Arons R. Radiation is a risk factor for colon cancer development in patients with primary cervical cancer. Gynecol Oncol 101(S119), 2006. e-Pub 2006.
Ascher-Walsh CJ, Meyer LA, Norman R, Wilkinson JP. Access to healthcare, patient comprehension during preoperative counseling, and understanding of future plans of women undergoing surgery for repair of a vesico-vaginal fistula in western Niger: A report from a survey given at the National Hospital Fistula Center, Niamey, Niger. Int Urogynecol J 17(Suppl. 3):S411-412, 2006. e-Pub 2006.
Awtrey C, Meyer LA, Kauff N Levine D, Barakat R. Primary peritoneal cancer (PPC) following bilateral salpingo-oophorectomy (BSO). Gynecol Oncol 96:934, 2005. e-Pub 2005.
Graham G, Meyer LA, Perez-Delboy A, Simpson L. The yield of congenital heart disease by indication for fetal echocardiogram. Journal of Ultrasound in Medicine 23(S101), 2004. e-Pub 2004.
Primm, KM, Zhao, H, Adjei, N, Sun, C, Haas, A, Meyer, L, Chang, S. Impact of Medicaid Expansion on Time to Treatment and Survival in Patients with Common Cancers.

Book Chapters

Huepenbecker, S, Meyer, LA. Patient reported outcomes (PROs), 193-215, 2022.
Huepenbecker SP, Meyer, LA. Patient reported outcomes (PROs): Considerations for implementation in your ERAS program. In: The ERAS® Society Handbook for Obstetrics & Gynecology. Elsevier Inc./Academic Press, 193-215, 2022.
Jhingran, A, Meyer, LA. Malignant diseases of the cervix, 674 and 690.e3, 2021.
Jhingran A, Meyer LA. Malignant Diseases of the Cervix - Microinvasive and Invasive Carcinoma: Diagnosis and Management. In: Comprehensive Gynecology. 7. Elsevier, 666-685, 2021.
Jhingran A, Meyer LA. Malignant Diseases of the Cervix Microinvasive and Invasive Carcinoma: Diagnosis and Management. In: Comprehensive Gynecology. 8. David Gershenson Gretchen Lentz Fidel Valea Rogerio Lobo, 912, 2021.
Meyer L, Ramirez P. Chapter 30: Functional Recovery at Home and After Discharge. In: Enhanced Recovery After Surgery - Complete Guide to Optimizing Outcomes. Springer; 1st ed, 285-289, 2020.
Nelson G, Bakkum-Gamez J, Altman A, Meyer LA, Pache J, Mena G, Pache B, Scott M, Ramirez P, Dowdy S. Chapter 46: Gynecologic/Oncology Surgery. In: Enhanced Recovery After Surgery (ERAS). Springer, 1st ed, 443-456, 2020.
Westin SN, Meyer LA, Coleman RL. Ovarian Cancer. In: Targeted Therapy in Translational Cancer Research. Wiley Blackwell, 240-254, 2015.
Meyer L, Pothuri B. Early Cervical Cancer. In: Gynecologic Tumor Board: Clinical Cases in Diagnosis and Management of Cancer of the Female Reproductive System. Jones and Bartlett Publishers, 145-156, 2009.

Letters to the Editor

Schuster ALR, Crossnohere NL, Boakye EA, Angove R, Baldwin B, Barreto EA, Chen RC, Gillespie TW, Hamilton B, McCleary NJ, Karmo M, Kaufmann T, Lee W, Mehta V, Meyer L, Mittal K, Owens L, Peterson R, Pusic A, Rainey AM, Richardson A, Shapiro L, Sibbitt B, Smith C, Vargo M, Vickers A, Brundage M, Snyder C. A Framework to Promote Implementation of Patient-Reported Outcomes in Institutions Caring for Vulnerable and Underserved Cancer Populations. Patient, 2024.
Charlton-Ouw KM, Meyer LA. Reply. J Vasc Surg Venous Lymphat Disord 8: 699-700, 2020.
Meyer LA, Wright AA. Reply to M.S. Copur et al. J Clin Oncol 35: 803, 2017.

Less

Selected Presentations & Talks

Local Presentations

2025. Opportunistic Salpingectomy. Invited. DIvision of Surgery Grand Rounds. Houston, Texas, US.
2025. Integrating Patient Reported Outcomes (PRO) Into Clinical Research. Invited. Gynecologic Oncology Clinical Research Education Series. Houston, Texas, US.
2019. Cases. Conference. Cases. Houston, TX, US.
2017. "Application of HSR Methods to Study a Health Care Movement: Enhanced Recovery after Surgery". Conference. "Application of HSR Methods to Study a Health Care Movement: Enhanced Recovery after Surgery". Houston, TX, US.
2014. "Patterns of Care and Overall Survival in the Medicare Ovarian Cancer Population". Conference. "Patterns of Care and Overall Survival in the Medicare Ovarian Cancer Population". Houston, TX, US.
2014. "In the trenches: A quality improvement project to improve HPV vaccination completion rates in an urban pediatric practice". Conference. "In the trenches: A quality improvement project to improve HPV vaccination completion rates in an urban pediatric practice". Houston, TX, US.
2014. "In the trenches: A quality improvement project to improve HPV vaccination completion rates in an urban pediatric practice: Practical strategies for improving HPV Vaccine Coverage". Conference. "In the trenches: A quality improvement project to improve HPV vaccination completion rates in an urban pediatric practice: Practical strategies for improving HPV Vaccine Coverage". Houston, TX, US.
2013. "In the trenches: A quality improvement project to improve HPV vaccination completion rates in an urban pediatric practice". Conference. "In the trenches: A quality improvement project to improve HPV vaccination completion rates in an urban pediatric practice". Houston, TX, US.

Regional Presentations

2012. "Ovarian Cancer" Advances in Oncology: From Clinical Science to Clinical Practice. Conference. "Ovarian Cancer" Advances in Oncology: From Clinical Science to Clinical Practice, US.
2012. “Update in HPV Vaccine and Screening”, Oral presentation, Family Medicine Grand Rounds. Conference. “Update in HPV Vaccine and Screening”, Oral presentation, Family Medicine Grand Rounds, US.
2011. “Primary Ovarian Cancer Therapy: Navigating the Options”. Oral Presentation, Second Annual Advances in Oncology: From Clinical Science to Clinical Practice. Conference. “Primary Ovarian Cancer Therapy: Navigating the Options”. Oral Presentation, Second Annual Advances in Oncology: From Clinical Science to Clinical Practice, US.
2011. “Can negative biomarkers be helpful? A novel combination test to predict non-response to inhibition of the mammalian target of rapamycin (mTOR) pathway in endometrial cancer”. Poster presentation. Conference. “Can negative biomarkers be helpful? A novel combination test to predict non-response to inhibition of the mammalian target of rapamycin (mTOR) pathway in endometrial cancer”. Poster presentation, US.
2010. "The Proper Pap: Implementation of Clinical Practice Guidelines Can Decrease Pap Test Overutilization During Disease Surveillance for Survivors of Gynecologic Malignancies”, Poster presentation. Conference. "The Proper Pap: Implementation of Clinical Practice Guidelines Can Decrease Pap Test Overutilization During Disease Surveillance for Survivors of Gynecologic Malignancies”, Poster presentation. Austin, TX, US.
2010. "The Proper Pap: Implementation of Clinical Practice Guidelines Can Decrease Pap Test Overutilization During Disease Surveillance for Survivors of Gynecologic Malignancies”, Poster presentation, Celebrating Improvement. Conference. "The Proper Pap: Implementation of Clinical Practice Guidelines Can Decrease Pap Test Overutilization During Disease Surveillance for Survivors of Gynecologic Malignancies”, Poster presentation, Celebrating Improvement, US.
2009. “Evaluating Women with Ovarian Cancer for BRCA 1 and BRCA2 Mutations: Missed Opportunities”. Oral presentation, Trainee Research Day 2009; Advances in Oncology Institutional Grand Rounds. Conference. “Evaluating Women with Ovarian Cancer for BRCA 1 and BRCA2 Mutations: Missed Opportunities”. Oral presentation, Trainee Research Day 2009; Advances in Oncology Institutional Grand Rounds, US.

National Presentations

2025. Trends in physical activity for ovarian cancer survivors completing primary therapy. Poster. Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer,. Seattle, WA, US.
2025. Exploring facets of quality of life of women experiencing recurrent ovarian cancer: Why does it matter?. Conference. Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer. Seattle, WA, US.
2024. Management of the Lynch patient. Invited. AAGL Global Congress: 53rd Global Congress on MIGS. New Orleans, LA, US.
2024. ERAS and Cancer Outcomes. Invited. American Society for Enhanced Recovery and Perioperative Medicine. Houston, TX, US.
2023. Financial Toxicity in Cancer Care. Conference. Financial Toxicity in Cancer Care. Whistler, US.
2023. Alternative and Fertility sparing surgical options for early stage cervical cancer. Conference. Alternative and Fertility sparing surgical options for early stage cervical cancer. Whistler, US.
2022. Compliance and Audit-How We Work-MD Anderson. Conference. Compliance and Audit-How We Work-MD Anderson, WA, US.
2021. New Surgical Approaches and Improving Recovery. Conference. 2021 Ovarian Cancer Survivors Course. Houston, TX, US.
2021. Treatment Implications of Genetic Testing Results: Systemic Therapy for Ovarian Cancer. Conference. 4th Annual Hereditary Cancer Symposium for Health Care Providers. Houston, TX, US.
2020. What is Recovery and how do we define recovery?. Conference. What is Recovery and how do we define recovery?. Houston, TX, US.
2020. Global Enhanced Recovery Symposium - Developing the Team. Conference. Global Enhanced Recovery Symposium - Developing the Team. Houston, TX, US.
2020. Financial toxicity and patient-reported outcomes over time: A longitudinal study of women with recurrent ovarian cancer. Conference. Financial toxicity and patient-reported outcomes over time: A longitudinal study of women with recurrent ovarian cancer, US.
2019. Clinical presentation - Pathobiology. Conference. Clinical presentation - Pathobiology. Panama City.
2018. Outcomes of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. Conference. Poster Presentation. New Orleans, LA, US.
2018. Patient-reported symptom burden and functional recovery before and after enhanced recovery after surgery (ERAS) implementation: A comparison between open and minimally invasive surgery. Conference. Scientific Plenary. New Orleans, LA, US.
2018. How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients. Conference. Poster Presentation. New Orleans, LA, US.
2018. Aggressive surgery in the elderly: National trends and outcomes associated with bowel and upper abdominal procedures in ovarian cancer surgery. Conference. Poster Presentation. New Orleans, LA, US.
2018. Variation of cost and resource utilization associated with the surgical management of women with ovarian cancer. Conference. Scientific Plenary. New Orleans, LA, US.
2018. Variation in unplanned readmission associated with the surgical management of women with ovarian cancer. Conference. Poster Presentation. New Orleans, LA, US.
2018. Personalized surgical algorithm for advanced ovarian cancer: Results from a prospective quality improvement project. Conference. Poster Presentation. New Orleans, LA, US.
2018. "Experts Discussion: Addressing the Upcoming Pitfalls of ERAS Programs". Conference. "Experts Discussion: Addressing the Upcoming Pitfalls of ERAS Programs". Houston, TX, US.
2018. "Role of Patient Reported Outcomes in an ERAS Program". Conference. "Role of Patient Reported Outcomes in an ERAS Program". Houston, TX, US.
2018. "Barriers to Compliance: How to Implement the Guidelines". Conference. "Barriers to Compliance: How to Implement the Guidelines". Houston, TX, US.
2018. "Implementation and Compliance: Developing a Process Map and Team". Conference. "Implementation and Compliance: Developing a Process Map and Team". Houston, US.
2017. Comparison of patient reported symptom burden in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Conference. Poster Presentation. Chicago, IL, US.
2017. Conservative management of bowel obstruction in ovarian cancer, management of stomal necrosis. Conference. Conservative management of bowel obstruction in ovarian cancer, management of stomal necrosis. Breckenridge, CO, US.
2017. Patient reported outcomes: impact on oncology care and delivery. Conference. Patient reported outcomes: impact on oncology care and delivery. Nashville, TN, US.
2016. Pain Management Techniques for Enhanced Recovery. Conference. Pain Management Techniques for Enhanced Recovery. New Britain, CT, US.
2016. Is recovery really "enhanced" through enhanced recovery programs? An analysis of patient-reported perioperative symptom burden before and after implementation of an enhanced recovery pathway for gynecologic surgery. Conference. Oral Scientific Plenary Presentation. San Diego, CA, US.
2016. Uptake and outcomes associated with neoadjuvant chemotherapy in the elderly: A population-based analysis. Conference. Poster Presentation. San Diego, CA, US.
2016. Value-based Cancer Care. Conference. Value-based Cancer Care. San Diego, CA, US.
2015. Comparison of Patient Reported Symptom Burden Pre- and Post- Implementation of an Enhanced Recovery Pathway for Gynecologic Surgery, Plenary Oral Presentation. Conference. Comparison of Patient Reported Symptom Burden Pre- and Post- Implementation of an Enhanced Recovery Pathway for Gynecologic Surgery, Plenary Oral Presentation. Washington, DC, US.
2015. Use of neoadjuvant chemotherapy in advanced ovarian cancer. Conference. Poster Presentation. Chicago, IL, US.
2015. Guidelines for Perioperative Care in Gynecologic Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations. Conference. Guidelines for Perioperative Care in Gynecologic Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations. Washington, DC, US.
2015. How to Incorporate QI into an Academic Career. Conference. How to Incorporate QI into an Academic Career. Houston, TX, US.
2015. Structured patient reminder systems and HPV vaccine completion rates: A quality improvement initiative. Conference. Poster Presentation. Chicago, IL, US.
2015. Patterns of care and survival in a matched case–control study of intraperitoneal chemotherapy in a national population-based cohort of elderly ovarian cancer patients. Conference. Poster Presentation. Chicago, IL, US.
2014. Parental Risk Perception and Decision Making Regarding Vaccination of their Eligible Children with the Human Papillomavirus Vaccine, Oral Presentation. Conference. Parental Risk Perception and Decision Making Regarding Vaccination of their Eligible Children with the Human Papillomavirus Vaccine, Oral Presentation. Miami, FL, US.
2014. Patterns of care and overall survival in the Medicare ovarian cancer population, Poster Presentation. Conference. Patterns of care and overall survival in the Medicare ovarian cancer population, Poster Presentation. Chicago, IL, US.
2014. Barriers to human papillomavirus (HPV) vaccination: Perspectives of parents of vaccine-eligible children, Poster Presentation. Conference. Barriers to human papillomavirus (HPV) vaccination: Perspectives of parents of vaccine-eligible children, Poster Presentation. Tampa, FL, US.
2014. In vitro and in vivo evaluation of active hexose correlated compound (AHCC) for the eradication of HPV, Poster Presentation. Conference. In vitro and in vivo evaluation of active hexose correlated compound (AHCC) for the eradication of HPV, Poster Presentation. Tampa, FL, US.
2014. Forgotten appointments equals missed opportunities: Exploring the reasons for low HPV vaccine series completion rates, Poster Presentation. Conference. Forgotten appointments equals missed opportunities: Exploring the reasons for low HPV vaccine series completion rates, Poster Presentation. Tampa, FL, US.
2013. Modern Advances in the Management of Rare Ovarian Tumors, Oral Presentation. Conference. Medical Oncology and Hematology 2013: Multidisciplinary Approaches that Improve Coordination of Care. Houston, TX, US.
2012. Development and implementation of Pap test guidelines in a GYN Oncology practice, Poster Presentation. Conference. 2012 Improvement Science Summit, The Academic Center for Evidence-based Practice. San Antonio, TX, US.
2012. Clinical Update: HPV associated gynecologic malignancies. Oral presentation. Conference. Clinical Update: HPV associated gynecologic malignancies. Oral presentation. Panama City, Panama, US.
2012. Can negative biomarkers be helpful? A novel combination test to predict non-response to inhibition of the mammalian target of rapamycin (mTOR) pathway in endometrial cancer. Poster presentation. Conference. Can negative biomarkers be helpful? A novel combination test to predict non-response to inhibition of the mammalian target of rapamycin (mTOR) pathway in endometrial cancer. Poster presentation. Austin, TX, US.
2011. The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer. Poster discussion. Conference. The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer. Poster discussion. Chicago, IL, US.
2011. Genetic variants in the mammalian target of rapamycin (mTOR) pathway as predictors of clinical response and survival in women with ovarian cancer. Oral presentation. Conference. Genetic variants in the mammalian target of rapamycin (mTOR) pathway as predictors of clinical response and survival in women with ovarian cancer. Oral presentation. Houston, TX, US.
2011. Genetic Variants in the mammalian target of rapamycin (mTOR) pathway as predictors of clinical response and survival in women with ovarian cancer. Oral Plenary Presentation. Conference. Genetic Variants in the mammalian target of rapamycin (mTOR) pathway as predictors of clinical response and survival in women with ovarian cancer. Oral Plenary Presentation. Orlando, FL, US.
2011. Clinical practice guidelines decrease unnecessary Pap tests in survivors of gynecologic malignancies. Featured Poster. Conference. Clinical practice guidelines decrease unnecessary Pap tests in survivors of gynecologic malignancies. Featured Poster. Orlando, FL, US.
2009. Evaluating Women with Ovarian Cancer for BRCA 1 and 2 Mutations: A Trend Over Time, Poster Presentation. Conference. Evaluating Women with Ovarian Cancer for BRCA 1 and 2 Mutations: A Trend Over Time, Poster Presentation. San Antonio, TX, US.
2008. Evaluating Women with Ovarian Cancer for BRCA 1/2: Missed Opportunities. Oral Presentation. Conference. Evaluating Women with Ovarian Cancer for BRCA 1/2: Missed Opportunities. Oral Presentation. Sonoma, CA, US.
2008. Evaluating Women with Ovarian Cancer for BRCA 1/2: Missed Opportunities. Poster discussion. Conference. Evaluating Women with Ovarian Cancer for BRCA 1/2: Missed Opportunities. Poster discussion. Chicago, IL, US.
2008. Faculty Member, American College of Obstetrics and Gynecology (ACOG) Annual Clinical Meeting Medical Student Program: Workshop #2 Finding the Shoes That Fit: Asking the Right Questions to Find the Residency Program That’s Right for You. Conference. Faculty Member, American College of Obstetrics and Gynecology (ACOG) Annual Clinical Meeting Medical Student Program: Workshop #2 Finding the Shoes That Fit: Asking the Right Questions to Find the Residency Program That’s Right for You. New Orleans, US.
2008. Panelist, Junior Fellow Luncheon Seminar: The ABC’s of Applying for Subspecialty Training (EV04). Conference. Panelist, Junior Fellow Luncheon Seminar: The ABC’s of Applying for Subspecialty Training (EV04). New Orleans, US.

International Presentations

2025. Neuroendocrine Carcinoma of the Cervix. Invited. Winter SGO. Whistler, CA.
2024. Multi-Team Reconstructive Disaster Case. Panelist. Society of Pelvic Surgeons: 72nd Meeting. Houston, US.
2024. Low Grade Tumors: Low grade serous ovarian cancer. Invited. 9th MD Anderson Cancer Center International Meeting in Gynecologic Oncology: “Steady Evidence in Turbulent Times”. Madrid, ES.
2024. Epidemiology of HPV vaccination. Invited. 9th MD Anderson Cancer Center International Meeting in Gynecologic Oncology: “Steady Evidence in Turbulent Times”. Madrid, ES.
2024. Tumor Board. Panelist. 9th MD Anderson Cancer Center International Meeting in Gynecologic Oncology: “Steady Evidence in Turbulent Times”. Madrid, ES.
2024. Expert Reviewer: Distillation of Plenary 04: Oral Abstract Presentations. Invited. IGCS Global Meeting 2024. Dublin, IE.
2024. POSTER ROUNDS 04: ENDOMETRIAL CANCER II. Panelist. IGCS Global Meeting 2024. Dublin, IE.
2021. Quality of Life in Gynaecological Oncology. Invited. The 13th Breast Gynecological and Immunoncology International Cancer Center. Cairo, EG.
2020. Financial toxicity and patient-reported outcomes over time: A longitudinal study of women with recurrent ovarian cancer. Invited. ASCO, US.
2019. Patients Reported Outcomes in Clinical Practice. Invited. 4º International Congress Clínica Astorga. Panama City, PA.
2019. Adjuvant front-line treatment options. Invited. 4º International Congress Clínica Astorga. Panama City, PA.
2019. Clinical presentation - Pathobiology. Invited. 4º International Congress Clínica Astorga. Panama City.
2019. BRCA Testing: Who, What, Where, When, How and Why?. Invited. 4º International Congress Clínica Astorga. Panama City, PA.
2019. MIS and PROs: Is Implementation in MIS Truly Worth It?. Invited. 7th ERAS World Congress. Liverpool, GB.
2019. Expert Input In Troubleshooting: What To Do When Issues Arise?. Invited. 7th ERAS World Congress. Liverpool, GB.
2018. A Phase III Prospective Randomized Trial Comparing Liposomal Bupivacaine vs. Standard Bupivacaine Wound Infiltration In Patients Undergoing Open Gynecologic Surgery On An Enhanced Recovery Pathway. Invited. Oral Plenary Presentation. Kyoto, JP.
2018. Opioid Consumption Day Prior To Discharge In Patients Undergoing Open Gynecologic Surgery In An ERAS Program: Developing A Model For Reduction In Narcotic Discharge Prescriptions. Invited. Oral Plenary Presentation. Kyoto, JP.
2018. Early recovery after surgery programs (ERAS). Invited. MD Anderson International Meeting in Gynecologic Oncology: Embracing New Standards of Care in Gynecologic Cancers. Madrid, ES.
2018. Impact of ERAS implementation on patient reported outcomes in open and minimally invasive surgery. Invited. ERAS 2018 World Congress. Stockholm, SE.
2018. Quality of life and patient reported outcomes. How do they inform clinical trials?. Invited. MD Anderson International Meeting in Gynecologic Oncology: Embracing New Standards of Care in Gynecologic Cancers. Madrid, ES.
2017. Comparison of patient reported symptom burden in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Invited. Poster Presentation. Chicago, US.
2017. How much Further can we Enhance Recovery? The role of ERAS in Minimally Invasive GYN Surgery. Invited. World Congress of Enhanced Recovery After Surgery, Gynecology Group Meeting -Women's Health Symposium. Lyon, FR.
2017. Cost comparison of resource utilization before and after implementing an enhanced recovery after surgery (ERAS) program-A significant impact on the ‘bottom line.’. Invited. Oral Plenary Presentation. Lyon, FR.
2017. Ongoing Trials Update: Patient Reported Outcomes in a Gynecology ERAS Program. Invited. World Congress of Enhanced Recovery After Surgery, Gynecology Group Meeting-Women's Health Symposium. Lyon, FR.
2017. Comparison of Patient Reported Symptom Burden Pre-and Post-Implementation of an Enhanced Recovery Pathway (ERP) for Gynecologic Surgery, Oral Presentation. Invited. International Meeting of The European Society of Gynaecological Oncology (ESGO), FR.
2016. Endometrial Hyperplasia and Cancer in Young Women: A Study of National Patterns of Care over Time and Pregnancy Outcomes. Invited. International Gynecologic Cancer Society. Lisbon, PT.
2016. Adoption of an Enhanced Recovery Program Leads to Decreased Patient Reported Opioid Related Adverse Events. Invited. Poster Presentation. Copenhagen, FR.
2015. Comparison of Patient Reported Symptom Burden Pre- and Post- Implementation of an Enhanced Recovery Pathway for Gynecologic Surgery, Plenary Oral Presentation. Invited. Proceedings of the 2015 World Congress of Enhanced Recovery after Surgery and Perioperative Medicine Annual Meeting. Washington, US.
2015. Use of neoadjuvant chemotherapy in advanced ovarian cancer. Invited. Poster Presentation. Chicago, US.
2015. Guidelines for Perioperative Care in Gynecologic Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations. Invited. Proceedings of the 2015 World Congress of Enhanced Recovery After Surgery and Perioperative Medicine Annual Meeting. Washington, US.
2014. Parental Risk Perception and Decision Making Regarding Vaccination of their Eligible Children with the Human Papillomavirus Vaccine, Oral Presentation. Invited. Proceedings of the 36th Annual Meeting of the Society for Medical Decision Making. Miami, US.
2014. Harnessing the power: The use of social media, SMS and next generation communication in cervical cancer, Oral Presentation. Invited. Indo-US workshop on Epidemiology and Prevention of Cancer, IN.
2014. Molecular epidemiology in gynecologic malignancies: Looking towards the future, Oral Presentation. Invited. Indo-US workshop on Epidemiology and Prevention of Cancer, IN.
2014. Patterns of care and overall survival in the Medicare ovarian cancer population, Poster Presentation. Invited. Proceedings of the Annual ASCO Meeting. Chicago, US.

Formal Peers

2025. Rare Cervical Cancer. Houston, Texas, US.
2018. Enhanced Recovery in Gynecology: The MD Anderson Experience. Invited. Enhanced Recovery in Gynecology: The MD Anderson Experience. Detroit, MI, US.
2018. Application of HSR Methods to Study a Health Care Movement: Enhanced Recovery After Surgery. Invited. Application of HSR Methods to Study a Health Care Movement: Enhanced Recovery After Surgery. Chicago, IL, US.
2016. Enhanced Recovery in Gynecology. Invited. Enhanced Recovery in Gynecology. Oklahoma City, OK, US.
2013. Gynecology in Central America. Invited. Gynecology in Central America. Panama City, Panama, PA.

Less

Grant & Contract Support

Date:	2023 - 2028
Title:	Optimizing Ovarian Cancer Primary Prevention through Mathematical Modeling
Funding Source:	NIH/NCI
Role:	PI
ID:	13819501

Date:	2023 - 2028
Title:	Preventing endometrial cancer through bariatric surgery and long acting reversible contraception
Funding Source:	NIH/NCI
Role:	PI
ID:	13819474

Date:	2022 - 2024
Title:	Engaging patients in decision making: The development and pilot testing of a low literacy Spanish language shared medical decision tool for ovarian cancer maintenance therapy
Funding Source:	Merck
Role:	PI
ID:	N/A

Date:	2022 - 2027
Title:	BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic Cancers – a Multi-Site Randomized Controlled Trial
Funding Source:	NIH/NCI
Role:	CO-I
ID:	N/A

Date:	2022 - 2024
Title:	Development of a risk prediction and natural history models for ovarian cancer
Funding Source:	UTMDACC Duncan Family Institute Seed Funding Research Program
Role:	CO-I

Date:	2022 - 2025
Title:	Understanding and intercepting ovarian carcinogenesis
Funding Source:	Break Through Cancer
Role:	PI
ID:	AWD00006455

Date:	2022 - 2025
Title:	Implementing an Intervention to Address Concerns of Older Patients with Cancer Receiving Chemotherapy and Their Caregivers
Funding Source:	Patient-Centered Outcomes Research Institute (PCORI)
Role:	PI
ID:	DI-2020C3_21003

Date:	2021 - 2025
Title:	PREPARE-OC Study: Patient-Reported Data Driven Predictions for Advanced Planning in End of Life Ovarian Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	00012509

Date:	2020 - 2024
Title:	Harnessing the Power of the Immune System to Combat Ovarian Cancer
Funding Source:	Dunwoody/Reese Ovarian Cancer Research
Role:	Gift Steward

Date:	2019 - 2021
Title:	Mediators of cancer related fatigue in ovarian cancer survivors: An exploration into molecules of resolution of inflammation and patient reported symptom burden
Funding Source:	Blanton Davis Ovarian Cancer Research Program
Role:	PI

Date:	2018 - 2021
Title:	Randomized Pilot of Self-Hypnosis to Improve Post-Operative Pain Outcomes and Reduce Opioid Intake in an ERAS Program
Funding Source:	Foundation For Womens Cancer
Role:	PI
ID:	FP00004133

Date:	2016 - 2017
Title:	Octopus PRO
Funding Source:	AstraZeneca
Role:	PI

Date:	2016 - 2021
Title:	Health Services Career Development: Improving Medical Decisions in Ovarian Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	CA201013

Date:	2015 - 2016
Title:	Minimally invasive gynecologic surgery: Can further improvements in recovery be made?
Funding Source:	MDACC, MINTOS Program
Role:	Principal Investigator-MDACC

Date:	2014 - 2025
Title:	AstraZeneca Strategic Alliance
Funding Source:	AstraZeneca
Role:	CO-I

Date:	2014 - 2025
Title:	Longitudinal study of patient reported outcomes, symptom burden, and quality of life among women newly diagnosed epithelial ovarian cancer
Funding Source:	Astra Zeneca
Role:	PI
ID:	2020-1294

Date:	2014 - 2024
Title:	Patterns of care and health outcomes for women with gynecologic malignancies
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	Principal Investigator-MDACC

Date:	2014 - 2016
Title:	CERCIT: Comparative Effectiveness Research on Cancer in Texas (C2: Training Core)
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Trainee
ID:	RP140020-C2

CV information above last modified March 31, 2025

Larissa A. Meyer, MD, MPH, FACOG, FACS

About Dr. Meyer

In the News

What to expect from an endometrial biopsy

The cancer vaccine

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Enhanced Recovery After Surgery (ERAS)

HPV-Related Cancers Moon Shot

Department of Gynecologic Oncology

Gynecologic Oncology Care Center

Help #EndCancer

Larissa A. Meyer, MD, MPH, FACOG, FACS

About Dr. Meyer

In the News

What to expect from an endometrial biopsy

The cancer vaccine

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Enhanced Recovery After Surgery (ERAS)

HPV-Related Cancers Moon Shot

Department of Gynecologic Oncology

Gynecologic Oncology Care Center

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer